

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Time matters – the fast growth of head and neck squamous cell carcinoma

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025359
Article Type:	Research
Date Submitted by the Author:	12-Jul-2018
Complete List of Authors:	Dejaco, Daniel; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Steinbichler, Teresa; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Schartinger, Volker; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Fischer, Natalie; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Anegg, Maria; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Dudas, Jozsef; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Posch, Andrea; Medical University of Innsbruck, Department of Radiationoncology Widmann, Gerlig; Medizinische Universitat Innsbruck, Department of Radiology Riechelmann, Herbert; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery
Keywords:	head and neck squamous cell carcinoma, tumour volume, tumour growth rate, EGFR, Ki67, CD44

SCHOLARONE™
Manuscripts

Time matters – the fast growth of head and neck squamous cell carcinoma

Dejaco D^{a,§} – Steinbichler T^a – Schartinger VH^a – Fischer N^a – Anegg M^a – Dudas J^a – Posch A^b –
Widmann G^c – Riechelmann H^a

^aDepartment of Otorhinolaryngology – Head and Neck Surgery, Medical University of Innsbruck,
Anichstr. 35, 6020 Innsbruck, Austria

^bDepartment of Radiationoncology, Medical University of Innsbruck, Anichstr. 35, 6020
Innsbruck, Austria

^cDepartment of Radiology, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck,
Austria

[§]Corresponding author:

Dejaco Daniel, MD

Department of Otorhinolaryngology – Head and Neck Surgery, Medical University of Innsbruck
Anichstr. 35, 6020 Innsbruck, Austria

Tel.: +43 512 504 23140 Fax: +43 512 504 23144 E-Mail: daniel.dejaco@i-med.ac.at

Word count: 3349

Abstract: 201

References: 30

Figures: 4

Tables: 4

ABSTRACT

Objectives: Data on tumour growth of head and neck squamous cell carcinoma (HNSCC) is sparse. We calculated specific growth rates (SGR) for the primary tumour (PT-SGR) and largest pathological cervical lymph nodes (LN-SGR) in patients with incident HNSCC treated with primary radiotherapy (RT) or radiochemotherapy (RCT).

Methods: In CT scans obtained at time of diagnosis and subsequent planning CTs immediately prior to RT or RCT, volumes of the primary tumour (PT-volume) and largest pathological cervical lymph node (LN-volume) were retrospectively measured. SGRs were calculated assuming an exponential growth function.

Results: In 123 patients, mean interval between diagnostic and planning CT was 29 ± 21 days. PT-SGR was $1.8\%\pm 1.8\%$ (mean \pm SD) per day and was positively correlated with EGFR, Ki67 and CD44 expression ($p=0.02$; $p=0.02$; $p=0.03$). LN-SGR was $1.7\%\pm 2.0\%$ per day and increased with larger initial LN-volume, was lower in laryngeal cancer ($p=0.003$) and slowed down with time. LN-SGR was not correlated with EGFR, Ki67 or CD44 expression in primary tumours ($p>0.12$). New cartilage or bone infiltration occurred in 10 patients and new central lymph node necrosis in 8 patients.

Conclusion: HNSCC are fast growing tumours for which treatment must not be delayed. Clinical tumour growth rates are influenced by EGFR, Ki67 and CD44 expression.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- In patients with incident head and neck squamous cell carcinoma (HNSCC), specific growth rates (SGR) for primary tumours (PT) and largest pathological cervical lymph nodes (LN) were retrospectively calculated.
- SGR in percentage growth per day was calculated from two CT scans obtained at time of diagnosis and subsequent planning CTs immediately prior to radiochemotherapy as previously described ($SGR = \ln[1^{st} \text{ volume} * 2^{nd} \text{ volume}] / [t2 - t1]$).
- Volumes in millilitres for PT and LN were calculated from maximum orthogonal diameters in all three planes applying an ellipsoid formula as previously described ($\text{volume} = (\pi * [x * y * z / 1000]) / 6$).
- To explore the impact of SGR of PT and LN on overall survival, Kaplan Maier and Cox regression models were used and SGRs were categorized in groups with slow (< 0.3%/day), intermediate ($0.3\% \leq 3\%$ /day) and rapid (>3%/day) SGRs.
- To explore the correlation of SGR with EGFR, Ki67 and CD44, Jonckheere-Terpstra tests were used and the percentage of positive cells grouped in 4 groups (0%, 1-30%, 31-60% and more than 60%).

KEYWORDS

head and neck squamous cell carcinoma; tumour volume; tumour growth rate; EGFR; Ki67;
CD44;

For peer review only

INTRODUCTION

In patients with head and neck squamous cell carcinoma (HNSCC), the median treatment waiting time in the US almost doubled from 19 to 30 days between 1998 and 2011. In a recent cancer registry based study, Murphy and co-authors analysed almost 275.000 patients with HNSCC of the most common cancer sites. The authors observed an independent effect of increased treatment waiting time on overall survival (OS)¹ and calculated 46 to 52 days as threshold for decreased OS². Similar observations were reported for oral cancer in a recent review including 18 studies³.

A likely reason for the association of treatment waiting time and decreased OS is meantime tumour growth. Mathematical models to approximate tumour growth from imaging data are available since the 1960s⁴. Originally, direct curve fitting to calculate tumor volume doubling time (DT) was the standard method to assess tumour growth. Recently, calculation of specific growth rate (SGR), defined as relative volume increase per unit of time, was proposed instead. It was reported more reliable for short time intervals and minor tumour volume differences.

Data on SGR of HNSCC is limited^{5 6}. A median SGR for primary tumours (PT-SGR) of 0.74% per day in patients with oropharyngeal HNSCC waiting for RCT was reported by Murphy and colleagues. The authors assessed the PT-SGR in 85 patients between diagnostic CTs and planning CTs and concluded that rapid PT-SGR may predict treatment failure in these patients⁵. Van Bockel and co-authors reported a significant association between high PT-SGR and decreased OS ($p=0.013$) in 131 patients with laryngeal HNSCC⁶.

In this retrospective study, we calculated SGR of the primary tumour (PT-SGR) and largest pathological cervical lymph node (LN-SGR) of patients with incident HNSCC from CTs obtained at diagnosis and from planning CTs obtained directly before RT/RCT. We investigated the influence of various factors including several biomarkers on PT-SGR and LN-SGR. We were further interested in the influence of SGR on OS and on the development of new lymph node necrosis and bone or cartilage infiltration.

MATERIALS AND METHODS

Tumour registry population

Patients referred to the Department of Otorhinolaryngology – Head and Neck Surgery, Medical University of Innsbruck, Austria, between 2008 and 2016 with incident histologically confirmed HNSCC were recorded in the clinical tumour registry. Disease was staged according to the seventh edition of the UICC TNM staging system⁷ by an interdisciplinary tumour board. Inclusion criteria comprised histologically proven incident HNSCC at any site of the head and neck region including cancer of unknown primary (CUP), any UICC Stage, RT or RCT as primary treatment and availability of both a diagnostic CT and a planning CT. The review board of the Medical University of Innsbruck had approved the study (UN4590) and informed consent was obtained from all study participants.

Diagnostic CT and planning CT

At the time of clinical diagnosis, diagnostic CT was performed following the standardized CT head & neck imaging protocols at the Department of Radiology, Medical University of Innsbruck. A GE-Medical Systems Light Speed VCT® or Light speed 16 CT scanner® (GE Medical, Vienna, Austria) was used. The scan area ranged from the frontal sinus to the upper mediastinum with a resolution of 512x512 pixels. Slices were calculated from raw data with 2 mm thickness, collimation of 24x1.2 mm and 0.45 pitch. Additional sagittal and coronal images were reconstructed. As contrast medium, Jopamiro 370® (Bracco Austria GmbH, Vienna, Austria) was administered intravenously adjusted to the patient's bodyweight. Planning CT scans were later performed at the Department of Radiation Oncology, Medical University of Innsbruck. Imaging protocols were followed as described above with the same CT scanners, contrast medium, scanning areas, resolutions and calculation protocols. Images from both CT scans were exported in Digital Imaging and Communications in Medicine (DICOM) format using IMPAX EE® (Agfa HealthCare, Bonn, Germany) Picture Archiving and Communication System (PACS®, Cerner, Kansas City USA). LN with a minimal axial diameter >10 mm, a central necrosis >3 mm or if present in neck levels close to the primary tumour in groups of >3 were classified pathological⁸.

Volume approximation, specific growth rate and tumour volume doubling time

Volumes were calculated as previously described⁹. In short, maximum orthogonal diameters in millimetres were measured for the primary tumour (PT) and the largest pathological cervical lymph (LN) in all three planes in axial and coronal sections (Figure 1). Volumes in millilitres were approximated employing an ellipsoid formula ($\text{volume} = (\pi * [x*y*z/1000])/6$). The largest cervical LN instead of all pathological cervical lymph nodes was considered sufficient for evaluation based on a high correlation previously observed⁹. Central lymph node necrosis and/or cartilage or bone infiltration of the primary tumour was recorded for additional analysis.

SGRs were assumed to be exponential and defined as the relative volume increase given in percent per day. For calculation of SGR, the equation described by Mehrara and co-authors was applied ($\text{SGR} = \ln[1^{\text{st}} \text{volume} * 2^{\text{nd}} \text{volume}]/[t_2 - t_1]$)¹⁰. For comparison with earlier studies, doubling times (DT) for primary tumours (PT-DT) and for largest pathological cervical lymph nodes (LN-DT) were calculated as the time difference * LN(2) divided by the logarithm of the volume ratio of the two observations¹¹.

Analysis of EGFR, Ki67 and CD44 expression

Tumour biopsies were collected in 4% buffered formalin, fixed overnight and embedded using the ethanol – isopropanol – wax quick 4mm protocol of Histos 5 embedding processor[®] (Milestone, Bergamo, Italy). Five-micrometre thick paraffin sections were dewaxed and antigen retrieval was performed in a Discovery automated staining system[®] (Ventana, Tucson, AZ, USA). Primary antibodies were added to the sections by automatic dispensing either as ready-to-use, pre-diluted, stabilized solutions provided by the manufacturers: cyclin dependent kinase inhibitor 2A (p16) INK4[®] (Ventana, Cat. Nr. 6595294001), Ki67 antigen (Ki67; Linaris E059[®], clone MIB-1[®], Dossenheim, Germany), CD44 antigen (CD44; Diagnostic Biosystems /Antibodies Online, ABIN1020059, Aachen, Germany) and Epidermal Growth Factor Receptor (EGFR; Invitrogen, Vienna, Austria). Immunohistochemical staining was completed by the Discovery automated staining system[®] (Ventana, Tucson, AZ, USA) using universal secondary antibody solution, haematoxylin counterstaining and the DAB MAP Kit (all Ventana products, Tucson, AZ, USA) as published previously¹². All sections were stained with control mouse and rabbit immunoglobulins, using the same highest concentration as for the primary antibodies, and

1
2
3 these controls were not reactive¹³. The immunohistochemical reactions were observed
4 independently by two blinded observers, who collected 10 representative tumour cell nests
5 from each specimen¹⁴. These regions were analysed on an Olympus BX50 microscope®
6 (Olympus, Tokyo, Japan) and the staining intensity and representation of tumour cell nests were
7 scored as previously described¹⁵. The cut-off for p16-positivity was 60% or more positive tumour
8 cells¹⁶.
9
10
11
12
13
14

15 **Data analysis**

16 Frequency data were presented in tabular form. For continuous data (volumes and growth
17 rates), means and standard deviations (SD) as well as medians and 25th (p25th) and 75th
18 percentiles (p75th) were provided. The median follow-up time was calculated as described by
19 Schemper and Smith¹⁷. Logarithmic transformation was used to analyse volumetric data in
20 regression models. Kruskal-Wallis and Jonckheere-Terpstra tests were used to evaluate the
21 univariate influence of ordinal factors on growth rates. For survival analyses, Kaplan Maier and
22 Cox regression models were used. For Kaplan Meier plots, growth rates were categorized in
23 groups with slow, intermediate and rapid growth rates. All calculations were performed with
24 SPSS 23.0 (IBM Corp., Armonk, NY).
25
26
27
28
29
30
31
32
33
34
35

36 **Patient and Public Involvement**

37 The development of the research question was based on previous publications exploring tumor
38 volume in HNSCC⁹ and its prognostic value if treated primarily with surgery¹⁸. Neither patients
39 nor the public were involved in the design of the study, the recruitment of the study or the
40 conduct of the study.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Study population

Between 2008 and 2016, 802 patients with incident HNSCC were recorded in the clinical cancer registry. Of 123 patients treated with primary RT or RCT, PT-volumes and LN-volumes were calculated from diagnostic and planning-CTs. In four patients with CUP-syndrome, no PT-volume and in 27 patients with N0 stage neck, no LN-volume could be measured. Of the 123 patients, 32 were female. The mean (\pm SD) age was 63 ± 10 years ranging from 38 to 87 years. Median follow up time was 45 months (95% confidence interval 42 to 48 months). Additional clinical data of the 123 included patients is provided in table 1.

Table 1: Clinical data of included 123 HNSCC patients.

		No. of patients
Sex	male	89
	female	32
Age	≤ 50 years	11
	51 – 60 years	42
	61 – 70 years	39
	71 – 80 years	26
	≥ 80 years	5
p16	negative	83
	positive	38
Tumour site	oral cavity	16
	oropharynx	55
	hypopharynx	24
	larynx	21
	other*	5
Clinical UICC stage	stage I	4
	stage II	7
	stage III	17
	stage IVa	75
	stage IVb	16
	stage IVc	2

Time interval, tumour and lymph node volumes

Mean (\pm SD) time interval between diagnostic CTs and planning CTs was 29 ± 21 days ranging from 6 to 146 days. For PT, a total of 119 volume sets from diagnostic CT and planning CT were available (Figure 2). Mean PT-volume from diagnostic CTs was $16.3 (\pm 20.4)$ mL ranging from 0 (CUP-syndrome) to 100.8 mL. Mean PT-volume from planning CTs was $24.5 (\pm 26.8)$ mL ranging from 0 to 160.3 mL. The mean PT-volume increase of $6.7 (\pm 17.2)$ mL during the period between 1st and 2nd CT scans was highly significant ($p < 0.001$).

For LN, a total of 96 volume sets were available (Figure 2). Mean LN-volume from diagnostic CTs was $9.2 (\pm 22.2)$ mL ranging from 0 (N0) to 156.2 mL. Mean LN-volume from planning CTs was $15.2 (\pm 31.5)$ mL ranging from 0 to 233.5 mL. The mean LN-volume increase of $5.3 (\pm 17.3)$ mL during the observation period was highly significant ($p < 0.001$). Distributions of these parameters were right skewed. Medians and quartiles for PT-volume and LN-volume are provided in table 2.

Table 2: Volumes of primary tumours and largest pathological cervical lymph nodes in diagnostic and planning CTs in 123 patients with HNSCC. Median time interval between 1st and 2nd CT scans was 24 days. Specific growth rates were calculated as suggested by Mehrara and co-authors¹⁰, tumour doubling-times were calculated as proposed by Schwartz¹¹.

	Diagnostic CT volume ¹⁾ [ml]	Planning CT volume ¹⁾ [ml]	SGR ²⁾ [%/day]	DT ³⁾
Primary tumour	9.4 (3.3; 21.4)	16.7 (5.4; 31.6)	1.4 (0.6; 2.7)	43 (24; 85)
Lymph node	2.0 (0.2; 9.5;)	3.7 (0.6; 19.4)	1.2 (0.3; 2.5)	41 (25; 80)

1) Median (25th and 75th percentile)

2) Specific growth rate (median, 25th and 75th percentile) percent per day

3) Tumour doubling time in days (median, 25th and 75th percentile)

Specific growth rates (SGR) and tumour doubling times (DT)

Mean (\pm SD) PT-SGR was $1.8\% \pm 1.8\%$ /day ranging from minus 2.6%/day (volume decrease) to 8.6%/day. Mean LN-SGR was $1.7\% \pm 2.0\%$ /day ranging from minus 1.5% to 11.0%/day. PT-SGR

and LN-SGR were right-skewed. For medians and quartiles see table 2. Mean PT-SGR of tumours of the oral cavity, oropharynx, hypopharynx and larynx were $3.1\pm 1.5\%$ /day, $1.8\pm 1.7\%$ /day, $2.0\pm 2.0\%$ /day and $1.5\pm 2.1\%$ /day, respectively. Mean LN-SGR for the primary tumour sites oral cavity, oropharynx, hypopharynx and larynx were $3.4\pm 3.9\%$ /day, $1.9\pm 2.2\%$ /day, $1.9\pm 1.4\%$ /day and $0.8\pm 1.1\%$ /day, respectively. For tumour sites, medians and quartiles are provided in table 3.

Table 3: Specific growth rates (SGR) for primary tumours (PT) and largest pathological cervical lymph nodes (LN) for common tumour sites of 123 patients with incident HNSCC.

Tumour site	n	PT-SGR ¹⁾	LN-SGR ¹⁾
Oral cavity	15	2.4 (1.0; 3.9)	0.8 (0.0; 1.5)
Oropharynx	55	1.4 (0.7; 2.6)	2.5 (0.4; 2.6)
Hypopharynx	25	1.7 (0.6; 2.7)	2.1 (0.6; 2.9)
Larynx	21	1.0 (0.3; 3.1)	0.8 (0.0; 1.4)
Others*	5	0.1 (0.0; 0.1)	1.4 (1.1; 5.2)

1) Median (25th and 75th percentile)

*including nasopharynx, paranasal sinuses and salivary glands

Median PT-DT was 43 days. The 25th percentile was 24 and the 75th percentile 85 days. Median LN-DT was 41 days. The 25th percentile was 25 and the 75th percentile 80 days (Tab. 2). PT-DT and LN-DT were considerably right skewed.

Factors influencing specific growth rates

PT-SGR was independent of the initial PT-volume in diagnostic CT ($p=0.19$). PT-SGR did also not depend on the interval between 1st and 2nd CT ($p=0.14$). Moreover, tumour site had no significant impact on SGR ($p=0.58$; Tab. 3). Interestingly, PT-SGR positively correlated with the expression of EGFR, Ki67 and CD44 ($p=0.02$; $p=0.02$ and $p=0.03$, respectively; Figure 3). The expression of p16 had no influence on PT-SGR ($p=0.21$).

In contrast, LN-SGR depended on the initial LN-volume measured in diagnostic CT ($p=0.003$) with higher LN-SGRs in lymph nodes with larger LN-volumes in the 1st CT. Also, the interval

1
2
3 between the diagnostic CT and planning CT significantly influenced LN-SGR ($p=0.003$). The
4 longer the interval, the lower the observed LN-SGR. Moreover, LN-SGR was significantly
5 influenced by tumour site ($p=0.032$; Tab. 3) with smallest growth rates in lymph nodes from
6 laryngeal HNSCC ($p=0.003$). In contrast to PT-SGR, neither EGFR, Ki67, CD44 nor p16 expression
7 in PTs significantly correlated with LN-SGR ($p=0.12$; $p=0.31$; $p=0.75$ and $p=0.81$, respectively).
8
9
10
11
12

13 **Specific-growth-rate and overall survival**

14
15 PT-SGR nearly missed significant impact on OS when used as a single covariate in a Cox
16 regression model (log rank $p=0.054$). For Kaplan Meier analyses, PT-SGR were categorized in 3
17 groups: slow ($< 0.3\%/day$; $n=22$); intermediate ($0.3\% \leq 3\%/day$; $n=73$) and rapid ($>3\%/day$;
18 $n=26$). Survival curves of these 3 SGR groups did not differ significantly (log rank $p=0.45$; Figure
19 4). Likewise, LN-SGR had no significant impact on OS as a covariate in Cox regression (log rank
20 $p=0.83$) nor in Kaplan Meier analyses (log rank $p=0.97$; data not shown).
21
22
23
24
25
26

27 **Cartilage or bone infiltration and central lymph node necrosis**

28
29 Cartilage or bone infiltration was observed in diagnostic CTs of 40/123 (33%) patients and in
30 planning CTs of 50/123 (41%) patients. Thus, during the median 24 days interval between the
31 two CTs, new cartilage or bone infiltration occurred in 10 patients, which was not influenced by
32 PT-SGR ($p=0.918$). However, cartilage or bone infiltration had a significant negative impact on
33 survival ($p=0.003$) and was significantly more frequent in p16 negative tumours ($p=0.02$).
34
35
36
37
38
39

40
41 Lymph node necrosis was observed in diagnostic CTs of 74/97 (76%) patients. LN-SGR was
42 significantly higher in patient with lymph node necrosis ($p<0.001$), was associated with poorer
43 survival ($p=0.03$) and did not depend on p16 status. Lymph node necrosis was observed in
44 planning CTs of 82/97 (85%) patients. Thus, during the median 24 days interval between the two
45 CTs, new lymph node necrosis occurred in 8 patients, which was not influenced by LN-SGR
46 ($p=0.818$). Central lymph node necrosis had a significant negative impact on survival ($p<0.05$).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Long waiting times for treatment of head and neck cancer result in decreased overall survival¹⁻³.

One reason might be meantime tumour growth. We examined tumour growth during the time between the initial diagnostic CT scan and the planning CT for RT or RCT in 123 patients with incident HNSCC. The mean interval between 1st and 2nd CT was 29 days ranging from 6 to 146 days. In this time, diagnostic work up, interdisciplinary tumour board presentation and pre-treatment procedures including dental treatments and application of percutaneous gastrostomies were carried out. PT- and LN-volumes in diagnostic and planning CTs were assessed using identical protocols. PT-SGR and LN-SGR were calculated as proposed by Mehrara and co-authors¹⁰.

Due to the skewness of volumetric data, the median is considered an appropriate measure of central tendency, but the mean is also provided for comparison with previous publications. Mean PT-volume in diagnostic CTs was approximately 16 mL (median≈9 mL). In planning CTs of the same patients 3-4 weeks later, mean PT-volume was approximately 25 mL (median≈17 mL; Tab. 2). These PT-volumes are in line with previous publications reporting mean volumes of 11-37 mL¹⁸⁻²¹. Mean LN-volume measured in diagnostic CTs was 9 mL (median≈2 mL) and approximately 15 mL (median≈4 mL) in planning CTs (Tab 2). Previously reported mean LN-volumes were considerably larger with 22-25 mL^{22,23}. However, in these studies the volume of all pathological cervical lymph nodes was measured instead of only the largest one as in this study.

Tumour and pathological lymph node growth can be reported as doubling time (DT) or specific growth rates (SGR). DT is the number of days the tumour needs to double its volume⁴. The lower the DT, the faster the tumour growth. Since DT was frequently reported in earlier studies, it was provided for comparison. SGR is defined as relative increase of volume in percent per day. The resulting variable is constant, linear and independent of the initially measured volumes¹⁰. SGR is considered less affected by measurement uncertainties of short time intervals and minor volume differences than DT¹⁰. For both, DT and SGR, tumour volumes are required. Since the reference method of slice-by-slice segmentation to measure PT- and LN-volumes is time-

1
2
3 consuming, a volume approximation method applicable over a wide range of PT and LN sizes
4 was used. This approximation is based on the measurement of maximum orthogonal diameters
5 employing an ellipsoid formula resulting in a slight underestimation of 8% of the PT-volume
6 measured with the reference method⁹. A similar approximation method has also been used by
7 Jensen and co-authors²⁴.
8
9

10
11
12
13
14 Mean primary tumour specific growth rates (PT-SGR) in incident HNSCC was 1.8%/day (Tab. 2),
15 unimodally distributed, slightly right skewed and independent of the initial PT-volume, which
16 supports the basic concept underlying SGR calculation. The interval between diagnostic CT and
17 planning CT did not influence PT-SGR ($p=0.1$), suggesting that no marked growth deceleration
18 occurred with longer waiting times. Interestingly, PT-SGRs did not significantly differ by tumour
19 site ($p=0.6$; Tab 3). Murphy and colleagues observed a lower median SGR of 0.74%/day in
20 patients with oropharyngeal cancer⁵. However, the authors did not include sites with faster
21 tumour growth such as the oral cavity (median SGR 2.4%/day) and hypopharynx (median SGR
22 2.0%/day). Moreover, most of the patients reported by Murphy and colleagues had T1 or T2
23 HNSCC and were p16 positive.
24
25
26
27
28
29
30
31
32
33

34 The median PT-DT in this study was 43 days. The 25th percentile was 24 and the 75th percentile
35 85 days. Median LN-DT was 41 days. The 25th percentile was 25 and the 75th percentile 80 days
36 (Tab. 2). Jensen and co-authors reported a slower growth rate in 61 patients with HNSCC with a
37 median PT-DT of 99 days. The authors however additionally stated that half of the patients
38 showed a faster growth rate with a PT-DT of 30 days²⁴. When compared with DT of other solid
39 tumours, this means that HNSCC reveal rapid tumour growth. For breast cancer, Ingebly and co-
40 authors reported a median DT of 285 days⁴. For lung cancer, DTs vary depending on histology
41 between median 42 days for metastases as reported by Loeffler and colleagues and 181 for non-
42 small-cellular lung cancer as reported by Winer-Muram and co-workers^{4 25}. For pancreatic
43 adenocarcinoma, Furkawa and colleagues reported a mean PT-DT of 144 days²⁵. For Sarcomas
44 median PT-DTs of 35 days were reported by Blomqvist and co-authors²⁵. Additional median PT-
45 DTs for additional solid tumours are provided in table 4.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4: Reported tumour volume doubling times for selected solid tumours*.

Tumour	Median DT [days]	n
Present study	47	123
HNSCC ²⁴	99**	61
Breast cancer ⁴	285	16
Lung bronchioalveolarcarcinoma ²⁵	181	9
Non small-cell lung carcinoma ²⁵	181	6
Lung metastasis ⁴	42	24
Pancreatic adenocarcinoma ²⁵	144	9
Sarcoma ²⁵	35	21

*modified after Mehrara and co-authors²⁵

**Jensen and co-workers also stated tumour volume doubling times for the faster growing half of the patients with a median PT-DT of 30²⁴.

PT-SGRs significantly correlated with the expression of EGFR, Ki67 and CD44 (p=0.021; p=0.018 and p=0.031, respectively) with higher PT-SGRs in patients with higher expression of the three biomarkers (Figure 3). These correlations appear biologically sound. A correlation of clinical tumour growth rates and expression of these biomarkers within the tumour of the same patients was not yet reported. EGFR is a cell surface receptor which promotes proliferation, invasion, angiogenesis and metastatic spread in HNSCC, if overexpressed²⁶. Ki-67 is a nuclear protein expressed on cells in all phases of the cell cycle except in G0-phase. Thus, its expression marks the total fraction of proliferating cells in a tumour²⁷. In laryngeal and hypopharyngeal SCC, an association between Ki67 expression and advanced tumour stages has been reported²⁸²⁹. In line with our observation of a correlation of CD44 expression and PT-SGR, an association between advanced T categories and high CD44 expressions has been reported in a meta-analysis including thirty studies with 2102 patients³⁰. No significant correlation between PT-SGR and p16 expression was observed (p=0.81). This observation differs from previous observations made by Murphy and colleagues. The authors observed that p16 expression correlated well with

1
2
3 PT-SGR with faster growth rates in p16 negative HNSCCs. However, the authors included
4 oropharyngeal HNSCC only and the majority (79%) were p16 positive tumours⁵. When used as a
5 covariate in a Cox model, PT-SGR had no significant effect on OS (log rank $p=0.054$). No
6 significant differences of survival curves were also observed, if PT-SGR were categorized in
7 groups of low, medium and high growth rates (log rank $p=0.5$; Figure 4). In contrast, van Bockel
8 and co-worker observed a significant association between PT-SGR and OS in laryngeal cancer⁶.
9
10
11
12
13
14
15

16 To our knowledge, no data on lymph node specific growth rates (LN-SGR) in HNSCC have been
17 previously reported. In the investigated patients, the mean LN-SGR was 1.7%/day, similar to
18 mean PT-SGR (Tab. 2). In contrast to PT-SGR, LN-SGR did depend on initial LN-volumes in
19 diagnostic CT scans ($p=0.003$) with higher LN-SGRs in lymph nodes with larger initial LN-
20 volumes. Also, the interval between diagnostic CT and planning CT significantly influenced LN-
21 SGR ($p=0.003$). The longer the interval, the lower the observed LN-SGR, suggesting growth
22 slowdown. Moreover, LN-SGR was significantly influenced by tumour site ($p=0.03$; Tab. 3), with
23 smallest growth rates in lymph nodes from laryngeal HNSCC. In contrast to PT-SGR, LN-SGR did
24 not depend on expressions of EGFR, Ki67, CD44 nor p16 expression in primary tumours
25 ($p=0.115$; $p=0.311$; $p=0.746$ and $p=0.809$ respectively). In LN, specific growth rates had no
26 significant impact on OS either ($p>0.05$).
27
28
29
30
31
32
33
34
35
36
37

38 New cartilage or bone infiltrations during the observation period were observed in 10 patients
39 and new central lymph node necroses were observed 8 patients. Specific growth rates had no
40 significant impact on the development of either of them. Both, initial cartilage or bone
41 infiltration and central lymph node necrosis were associated with worse survival. However,
42 probably due to the low number of events, no significant impact of new cartilage or bone
43 infiltration and central lymph node necrosis were associated with worse survival. However,
44 probably due to the low number of events, no significant impact of new cartilage or bone
45 infiltration nor new central lymph node necrosis on survival was observed in Kaplan Meier
46 analysis (both log rank $p>0.05$).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CONCLUSION

Head and neck squamous cell carcinomas are rapidly growing malignancies. Primary tumours and lymph nodes grow more than 1% per day. Consequently, time matters, and treatment must not be delayed.

For peer review only

ABBREVIATIONS

CD44	CD44 antigen
CT	computed tomography
DICOM	Digital Imaging and Communications in Medicine
DT	tumour volume doubling time
EGFR	epidermal growth factor receptor
HNSCC	head and neck squamous cell carcinoma
Ki67	Ki67 antigen
LN	largest pathological cervical lymph node
LN-DT	largest pathological cervical lymph node doubling time
LN-SGR	largest pathological cervical lymph node specific growth rate
p16	Cyclin-dependent kinase inhibitor 2A
PACS	Picture Archiving and Communication System
PT	primary tumour
PT-DT	primary tumour volume doubling time
PT-SGR	primary tumour specific growth rate
RCT	radiochemotherapy
RT	radiotherapy
SD	standard deviation
SGR	specific growth rate
TNM	tumour, node, metastasis
UICC	Union internationale contre le cancer

REQUIRED STATEMENTS

Acknowledgements

This work has not yet been previously presented at a conference or as a conference abstract.

Copyright statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

Ethics statement

The review board of the Medical University of Innsbruck had approved the study (UN4590) and informed consent was obtained from all study participants. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Competing interest and funding statement

All authors have completed the Unified Competing Interest form and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Contributorship statement

Daniel Dejaco has written major parts of the manuscript and performed the calculations of tumour and lymph node volumes. Teresa Steinbichler was involved in establishing the study concept, design and the internal review process of the manuscript. Schartinger Volker established the population based tumour registry from which patients were enrolled. He further obtained the ethics committee approval for the study. Natalie Fischer performed additional tumor and pathological cervical lymph node measurements and was involved in the internal

1
2
3 review process of the manuscript. Maria Anegg has performed additional calculations and data
4 base work in the population based tumour registry. Jozef Dudas performed the
5 immunohistochemical staining of the tumour biopsies and was involved in establishing the
6 study concept, design and the internal review process of the manuscript. Andrea Posch
7 provided the radiotherapy-planning CT scans and performed performed additional tumor and
8 pathological cervical lymph node measurements. Gerlig Widmann supervised the tumor and
9 pathological cervical lymph node measurements as an experienced head and neck radiologist.
10 Herbert Riechelmann supervised the writing process of the manuscript and performed all
11 statistical calculations in the manuscript.
12
13
14
15
16
17
18
19

20 21 **Transparency declaration**

22 The Corresponding Author affirms that the manuscript is an honest, accurate, and transparent
23 account of the study being reported; that no important aspects of the study have been omitted;
24 and that any discrepancies from the study have been explained.
25
26
27
28

29 **Details of ethical approval and patient consent**

30 The review board of the Medical University of Innsbruck had approved the study (UN4590) and
31 informed consent was obtained from all study participants.
32
33
34

35 **Data sharing**

36 No additional data from the study is available.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Murphy CT, Galloway TJ, Handorf EA, et al. Increasing time to treatment initiation for head and neck cancer: an analysis of the National Cancer Database. *Cancer* 2015;121(8):1204-13. doi: 10.1002/cncr.29191 [published Online First: 2014/12/11]
2. Murphy CT, Galloway TJ, Handorf EA, et al. Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States. *J Clin Oncol* 2016;34(2):169-78. doi: 10.1200/jco.2015.61.5906 [published Online First: 2015/12/03]
3. Stefanuto P, Doucet JC, Robertson C. Delays in treatment of oral cancer: a review of the current literature. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2014;117(4):424-9. doi: 10.1016/j.oooo.2013.12.407 [published Online First: 2014/02/22]
4. Steel GG, Lamerton LF. The growth rate of human tumours. *Br J Cancer* 1966;20(1):74-86. [published Online First: 1966/03/01]
5. Murphy CT, Devarajan K, Wang LS, et al. Pre-treatment tumor-specific growth rate as a temporal biomarker that predicts treatment failure and improves risk stratification for oropharyngeal cancer. *Oral Oncol* 2015;51(11):1034-40. doi: 10.1016/j.oraloncology.2015.09.001 [published Online First: 2015/09/28]
6. van Bockel LW, Verduijn GM, Monnikhof EM, et al. The importance of actual tumor growth rate on disease free survival and overall survival in laryngeal squamous cell carcinoma. *Radiother Oncol* 2014;112(1):119-24. doi: 10.1016/j.radonc.2014.06.004 [published Online First: 2014/07/06]
7. Sobin L WC. TNM Classification of Malignant Tumours: Wiley-Blackwell 2009.
8. van den Brekel MW, Stel HV, Castelijns JA, et al. Cervical lymph node metastasis: assessment of radiologic criteria. *Radiology* 1990;177(2):379-84. doi: 10.1148/radiology.177.2.2217772 [published Online First: 1990/11/01]
9. Dejaco D, Url C, Schartinger VH, et al. Approximation of head and neck cancer volumes in contrast enhanced CT. *Cancer Imaging* 2015;15:16. doi: 10.1186/s40644-015-0051-3 [published Online First: 2015/10/01]
10. Mehrara E, Forssell-Aronsson E, Ahlman H, et al. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. *Cancer Res* 2007;67(8):3970-5. doi: 10.1158/0008-5472.can-06-3822 [published Online First: 2007/04/19]
11. Schwartz M. A biomathematical approach to clinical tumor growth. *Cancer* 1961;14:1272-94. [published Online First: 1961/11/01]
12. Dudas J, Schartinger VH, Romani A, et al. Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer. *Tumour Biol* 2014;35(8):7807-19. doi: 10.1007/s13277-014-2001-2 [published Online First: 2014/05/13]
13. Schartinger VH, Falkeis C, Laimer K, et al. Neuroendocrine differentiation in head and neck squamous cell carcinoma. *J Laryngol Otol* 2012;126(12):1261-70. doi: 10.1017/S0022215112002265
14. Rietbergen MM, Snijders PJ, Beekzada D, et al. Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. *Int J Cancer* 2014;134(10):2366-72. doi: 10.1002/ijc.28580 [published Online First: 2013/11/20]

15. Smilek P, Dusek L, Vesely K, et al. Correlation of expression of Ki-67, EGFR, c-erbB-2, MMP-9, p53, bcl-2, CD34 and cell cycle analysis with survival in head and neck squamous cell cancer. *J Exp Clin Cancer Res* 2006;25(4):549-55. [published Online First: 2007/02/22]
16. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. *Int J Cancer* 2007;120(8):1731-8. doi: 10.1002/ijc.22355 [published Online First: 2007/01/20]
17. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. *Control Clin Trials* 1996;17(4):343-6. [published Online First: 1996/08/01]
18. Dejaco D, Steinbichler T, Schartinger VH, et al. Prognostic value of tumor volume in patients with head and neck squamous cell carcinoma treated with primary surgery. *Head Neck* 2018;40(4):728-39. doi: 10.1002/hed.25040 [published Online First: 2017/12/23]
19. Davis KS, Lim CM, Clump DA, et al. Tumor volume as a predictor of survival in human papillomavirus-positive oropharyngeal cancer. *Head Neck* 2016;38 Suppl 1:E1613-7. doi: 10.1002/hed.24287 [published Online First: 2015/12/19]
20. Kneegens JL, Hauptmann M, Pameijer FA, et al. Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. *Head Neck* 2011;33(3):375-82. doi: 10.1002/hed.21459 [published Online First: 2010/07/16]
21. Oemus D, Inhestern J, Schmalenberg H, et al. Prognostic value of tumor volumetry data of routine imaging data in a head and neck cancer registry. *Eur Arch Otorhinolaryngol* 2014;271(9):2531-7. doi: 10.1007/s00405-013-2800-x [published Online First: 2013/11/07]
22. Chen SW, Yang SN, Liang JA, et al. Prognostic impact of tumor volume in patients with stage III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy. *Head Neck* 2009;31(6):709-16. doi: 10.1002/hed.21011 [published Online First: 2009/03/05]
23. Doweck I, Denys D, Robbins KT. Tumor volume predicts outcome for advanced head and neck cancer treated with targeted chemoradiotherapy. *Laryngoscope* 2002;112(10):1742-9. doi: 10.1097/00005537-200210000-00006 [published Online First: 2002/10/09]
24. Jensen AR, Nellesmann HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. *RadiotherOncol* 2007;84(1):5-10.
25. Mehrara E, Forssell-Aronsson E, Ahlman H, et al. Quantitative analysis of tumor growth rate and changes in tumor marker level: specific growth rate versus doubling time. *Acta Oncol* 2009;48(4):591-7. doi: 10.1080/02841860802616736 [published Online First: 2009/03/31]
26. Bossi P, Resteghini C, Paielli N, et al. Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. *Oncotarget* 2016;7(45):74362-79. doi: 10.18632/oncotarget.11413 [published Online First: 2016/08/25]
27. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol* 2000;182(3):311-22. doi: 10.1002/(sici)1097-4652(200003)182:3<311::Aid-jcp1>3.0.Co;2-9 [published Online First: 2000/02/01]
28. Ashraf MJ, Maghbul M, Azarpira N, et al. Expression of Ki67 and P53 in primary squamous cell carcinoma of the larynx. *Indian J Pathol Microbiol* 2010;53(4):661-5. doi: 10.4103/0377-4929.72019 [published Online First: 2010/11/04]

- 1
2
3 29. Wang JX, Zhang YY, Yu XM, et al. Role of centromere protein H and Ki67 in relapse-free
4 survival of patients after primary surgery for hypopharyngeal cancer. *Asian Pac J Cancer*
5 *Prev* 2012;13(3):821-5. [published Online First: 2012/05/29]
6
7 30. Chen J, Zhou J, Lu J, et al. Significance of CD44 expression in head and neck cancer: a
8 systemic review and meta-analysis. *BMC Cancer* 2014;14:15. doi: 10.1186/1471-2407-
9 14-15 [published Online First: 2014/01/15]
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1: Tumour growth assessment using maximal orthogonal tumour diameters from axial contrast enhanced diagnostic CT scans (A) and subsequent planning CT scans (B)

Axial contrast enhanced diagnostic CT scan (A) and subsequent planning CT scan (B) 46 days later of a cT4a cN2b cM0 squamous cell carcinoma of the oral cavity. The maximum anterior-posterior and medio-lateral tumour diameters (white lines) were measured from axial scans, the cranio-caudal tumour diameters were measured from corresponding coronal scans (not depicted). The tumour volume was assessed as previously described using an ellipsoid formula⁹. PT-volume from diagnostic CT was 14.8 mL, PT-volume from planning CT was 51.0 mL translating to a PT-SGR of 2.8%/day.

1
2
3 **Figure 2: Correlation of primary tumour volume (A) and largest pathological lymph node**
4 **volume (B) measured from diagnostic CT scans and a planning CT scans**

5
6 Scattergram of primary tumour volumes (A) and largest pathological lymph node volume (B)
7 measured from diagnostic CT scans (x-axis) planning CT scans (y-axis). Both axes are on log scale.
8
9 The diagonal line represents the line of identity. Dots above this line indicate volume increases.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3: Specific growth rates of the primary tumours and percentage of Ki67 positive cells

Percentage of Ki67 positive immunohistochemistry in tumour samples of HNSCC patients and according primary tumour specific growth rates. The percentage of Ki67 positive cells was grouped in 0%, 1 to 30%, 31 to 60% and more than 60% of cancer cells (x-axis). Mean specific growth rates of HNSCC primary tumour (y-axis) were obtained 119 patients. Small bars represent standard deviation. PT-SGR positively correlated with the expression of Ki67 (Jonckheere-Terpstra $p=0.02$).

1
2
3 **Figure 4: Kaplan Maier plot for specific growth rates of primary tumours grouped by low,**
4 **medium and high growth rate**
5

6
7 Kaplan Maier plot of specific growth rates (SGR) of primary tumours grouped by low (black line;
8 SGR < 0.3%/day; n=22); medium (dark grey line; $0.3\% \leq \text{SGR} < 3\%$ /day; n=73) and high (pale grey
9 line; SGR >3%/day; n=26) growth rates. X-axis represents time in months, Y-axis overall survival.
10
11 The survival curves of the 3 specific growth rate groups did not differ significantly (log rank
12 p=0.45).
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Tumour growth assessment using maximal orthogonal tumour diameters from axial contrast enhanced diagnostic CT scans (A) and subsequent planning CT scans (B)
Axial contrast enhanced diagnostic CT scan (A) and subsequent planning CT scan (B) 46 days later of a cT4a cN2b cM0 squamous cell carcinoma of the oral cavity. The maximum anterior-posterior and medio-lateral tumour diameters (white lines) were measured from axial scans, the cranio-caudal tumour diameters were measured from corresponding coronal scans (not depicted). The tumour volume was assessed as previously described using an ellipsoid formula⁹. PT-volume from diagnostic CT was 14.8 mL, PT-volume from planning CT was 51.0 mL translating to a PT-SGR of 2.8%/day.

11x7mm (600 x 600 DPI)




Figure 2: Correlation of primary tumour volume (A) and largest pathological lymph node volume (B) measured from diagnostic CT scans and a planning CT scans
Scattergram of primary tumour volumes (A) and largest pathological lymph node volume (B) measured from diagnostic CT scans (x-axis) planning CT scans (y-axis). Both axes are on log scale. The diagonal line represents the line of identity. Dots above this line indicate volume increases.

16x7mm (600 x 600 DPI)




Figure 3: Specific growth rates of the primary tumours and percentage of Ki67 positive cells
Percentage of Ki67 positive immunohistochemistry in tumour samples of HNSCC patients and according primary tumour specific growth rates. The percentage of Ki67 positive cells was grouped in 0%, 1 to 30%, 31 to 60% and more than 60% of cancer cells (x-axis). Mean specific growth rates of HNSCC primary tumour (y-axis) were obtained 119 patients. Small bars represent standard deviation. PT-SGR positively correlated with the expression of Ki67 (Jonckheere-Terpstra $p=0.02$).

16x14mm (600 x 600 DPI)




Figure 4: Kaplan Maier plot for specific growth rates of primary tumours grouped by low, medium and high growth rate

Kaplan Maier plot of specific growth rates (SGR) of primary tumours grouped by low (black line; SGR < 0.3%/day; n=22); medium (dark grey line; $0.3\% \leq \text{SGR} < 3\%$ /day; n=73) and high (pale grey line; SGR > 3%/day; n=26) growth rates. X-axis represents time in months, Y-axis overall survival. The survival curves of the 3 specific growth rate groups did not differ significantly (log rank $p=0.45$).

16x14mm (600 x 600 DPI)

STROBE Statement: “Time matters – the fast growth of head and neck squamous cell carcinoma”

	Item No	Answer
Title and abstract	1	(a) The retrospective study design was described in the “Abstract” section, page 2, line 7, the “Strengths and Limitations of the Study” section, page 3 and the “Introduction” section, page 5. (b) An informative and balanced summary of what was done was provided in the “Abstract” section, page 2.
Introduction		
Background/rationale	2	The scientific background and rationale for the investigation was reported in the “Introduction” section of the manuscript, page 5.
Objectives	3	The objective of the study was specified in the “Abstract” section, page 2 and at the end of the “Introduction” section, page 2.
Methods		
Study design	4	Key elements of the study design were mentioned early in the “Abstract” section, page 2 and the “Introduction” section, page 5 of the manuscript. Additional details of the study design were outlined in the “Methods”, page 6 to 8.
Setting	5	The setting, location, relevant dates, including period of recruitment and data collection was included in the “Methods” section, page 6 and in the “Results” section, page 9.
Participants	6	(a) <i>Cohort study</i> — The eligibility criteria and the sources and methods of selection of participants are provided in detail in the “Methods” section, page 6. (b) <i>Cohort study</i> — No matching was performed in this study.
Variables	7	All outcomes, predictors, potential confounders and effect modifiers were defined, presented and discussed in the “Methods” section, page 6 to 8, “Results” section, page 9 to 12 and “Discussion” section, page 13 to 16. Diagnostic criteria were provided in the “Methods” section, page 6, when applicable.
Data sources/ measurement	8*	Source of data and details of methods was provided in the “Methods” section, page 6 and 8.
Bias	9	Potential sources of bias were addressed in the “Discussion” section, page 13 to 16.
Study size	10	An explanation how the study size was arrived at was provided in the “Method” section, page 6.
Quantitative variables	11	An explanation how quantitative variables were handled in the analyses was provided in the “Methods” section, page 8.
Statistical methods	12	(a) All statistical methods were described in the “Methods” section, page 8. (b) All methods for subgroup analyses of the presented study were described in the “Methods” section, page 8. (c) An explanation how missing data was addressed was provided in the “Methods” section, page 8, “Results” section, pages 9 to 12 and “Discussion” section, pages 13 to 16. (d) <i>Cohort study</i> —No loss to follow-up occurred due to the study design. (e) No sensitivity analyses were performed in the study.

Continued on next page

Results		
Participants	13*	(a) Numbers of individuals at each stage of the study was reported in the “Results” section, page 9 and the “Discussion” section, page 13. (b) No non-participation occurred due to the study design. (c) No flow diagram was used for this study.
Descriptive data	14*	(a) Clinical characteristics of study participants were provided in table 1, page 9. (b) Number of participants with missing data for each variable of interest was provided in the “Results” section, page 9 and in table 1, page 9. (c) <i>Cohort study</i> —Follow-up time was summarised as time between diagnostic computed tomography scan and planning computed tomography scan in this study provided in the “Results” section, page 9.
Outcome data	15*	<i>Cohort study</i> — Numbers of outcome events was provided in the “Results” section, page 9 to 12.
Main results	16	(a) Means, medians, standard deviations, 95% confidence intervals and 25 th and 75 th percentiles were provided in the “Results” section, page 9 to 12, if applicable. (b) Category boundaries for continuous variables were specified in the “Methods” section, page 8 and “Results” section, pages 9 to 12. (c) No relative risk estimations were performed in this study.
Other analyses	17	All additional other analyses performed in the study were outlined in the “Methods” section, page 8 and “Results” section, pages 9 to 12.
Discussion		
Key results	18	Key results with reference to previously outlined study objectives were summarised in the “Discussion” section, pages 13 to 16.
Limitations	19	Limitations of the study, taking into account sources of potential bias and imprecision were outlined in the “Discussion” section, pages 13 to 16.
Interpretation	20	A cautious overall interpretation of the results was given in the “Discussion”, pages 13 to 16 and the “Conclusion” section, page 17.
Generalisability	21	The external validity of the study results was outlined in the “Discussion” section, pages 13 to 16 and table 4, page 15.
Other information		
Funding	22	No financial support for any of the work presented in the present manuscript was obtained, provided on page 19.

BMJ Open

Specific growth rates calculated from computed tomographies in patients with head and neck squamous cell carcinoma: a retrospective study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025359.R1
Article Type:	Research
Date Submitted by the Author:	27-Nov-2018
Complete List of Authors:	Dejaco, Daniel; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Steinbichler, Teresa; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Schartinger, Volker; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Fischer, Natalie; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Anegg, Maria; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Dudas, Jozsef; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Posch, Andrea; Medical University of Innsbruck, Department of Radiationoncology Widmann, Gerlig; Medizinische Universitat Innsbruck, Department of Radiology Riechelmann, Herbert; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Ear, nose and throat/otolaryngology, Diagnostics, Radiology and imaging
Keywords:	head and neck squamous cell carcinoma, tumour volume, tumour growth rate, EGFR, Ki67, CD44

SCHOLARONE™
Manuscripts

1
2
3 1 **Specific growth rates calculated from computed tomographies in patients with head**
4 **and neck squamous cell carcinoma: a retrospective study**
5
6 2
7 3

8
9 4 Dejaco D^{a,§} – Steinbichler T^a – Schartinger VH^a – Fischer N^a – Anegg M^a – Dudas J^a – Posch A^b –
10
11 5 Widmann G^c – Riechelmann H^a
12
13 6

14
15 7 ^aDepartment of Otorhinolaryngology – Head and Neck Surgery, Medical University of Innsbruck,
16
17 8 Anichstr. 35, 6020 Innsbruck, Austria

18
19 9 ^bDepartment of Radiationoncology, Medical University of Innsbruck, Anichstr. 35, 6020
20
21 10 Innsbruck, Austria

22
23 11 ^cDepartment of Radiology, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck,
24
25 12 Austria
26
27 13

28 14 [§]Corresponding author:

29 15 Dejaco Daniel, MD

30
31 16 Department of Otorhinolaryngology – Head and Neck Surgery, Medical University of Innsbruck
32
33 17 Anichstr. 35, 6020 Innsbruck, Austria

34
35 18 Tel.: +43 512 504 23140 Fax: +43 512 504 23144 E-Mail: daniel.dejaco@i-med.ac.at
36
37 19

38 20 Word count: 3848

39 21 Abstract: 238

40 22 References: 32

41 23 Figures: 4

42 24 Tables: 4
43
44
45
46
47
48 25
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 ABSTRACT**

4 **2 OBJECTIVE:** To provide data on specific growth rates (SGR) of primary tumours (PT-SGR) and
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
largest pathological cervical lymph nodes (LN-SGR) for head and neck squamous cell carcinoma (HNSCC). To explore PT-SGR's and LN-SGR's correlation with selected biomarkers EGFR, Ki67 and CD44.

6 **DESIGN AND SETTING:** Retrospective study performed at a tertiary oncologic referral centre in
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Innsbruck, Austria.

8 **PARTICIPANTS:** Adult patients with incident HNSCC treated with primary radiotherapy (RT) or
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
radiochemotherapy (RCT).

10 **OUTCOME MEASURES:** Volumes of the primary tumour (PT-volume) and largest pathological
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
cervical lymph node (LN-volume) were measured in computed tomography (CT) scans obtained at time of diagnosis and subsequent planning CTs immediately prior to RT or RCT. SGRs were calculated assuming an exponential growth function. PT-SGR's and LN-SGR's correlation with EGFR, Ki67 and CD44 were explored.

15 **RESULTS:** In 123 patients, mean interval between diagnostic and planning CT was 29±21 days.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
PT-SGR was 1.8%±1.8% (mean±SD) per day and was positively correlated with EGFR, Ki67 and CD44 expression (p=0.02; p=0.02; p=0.03). LN-SGR was 1.7%±2.0% per day and increased with larger initial LN-volume, was lower in laryngeal cancer (p=0.003) and slowed down with time. LN-SGR was not correlated with EGFR, Ki67 or CD44 expression in primary tumours (p>0.12). New cartilage or bone infiltration occurred in 10 patients and new central lymph node necrosis in 8 patients.

22 **CONCLUSIONS:** HNSCC are fast growing tumours for which treatment must not be delayed.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Clinical tumour growth rates are influenced by EGFR, Ki67 and CD44 expression.

1 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 2 • In patients with incident head and neck squamous cell carcinoma (HNSCC), specific
3 growth rates (SGR) for primary tumours (PT) and largest pathological cervical lymph
4 nodes (LN) were retrospectively calculated.
- 5 • SGR in percentage growth per day was calculated from two CT scans obtained at time of
6 diagnosis and subsequent planning CTs immediately prior to radiochemotherapy as
7 previously described ($SGR = \ln[1^{st} \text{volume} * 2^{nd} \text{volume}] / [t_2 - t_1]$).
- 8 • Volumes in millilitres (mL) for PT and LN were calculated from maximum orthogonal
9 diameters in all three planes applying an ellipsoid formula as previously described
10 ($\text{volume} = (\pi * [x * y * z / 1000]) / 6$).
- 11 • To explore the impact of SGR of PT and LN on overall survival, Kaplan Maier and Cox
12 regression models were used and SGRs were categorized in groups with slow (<
13 0.3%/day), intermediate ($0.3\% \leq 3\%/\text{day}$) and rapid ($>3\%/\text{day}$) SGRs.
- 14 • To explore the correlation of SGR with EGFR, Ki67 and CD44, Jonckheere-Terpstra tests
15 were used and the percentage of positive cells grouped in 4 groups (0%, 1-30%, 31-60%
16 and more than 60%).
- 17 • Limitations include retrospective study design, small number of patients, small interval
18 of observation, lack of more modern imaging- and segmentation techniques.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **KEYWORDS**

- 2 head and neck squamous cell carcinoma; tumour volume; tumour growth rate; EGFR; Ki67;
3 CD44;

For peer review only

1 INTRODUCTION

2 In patients with head and neck squamous cell carcinoma (HNSCC), the median treatment
3 waiting time in the US almost doubled from 19 to 30 days between 1998 and 2011. In a recent
4 cancer registry based study, Murphy and co-authors analysed almost 275.000 patients with
5 HNSCC of the most common cancer sites. The authors observed an independent effect of
6 increased treatment waiting time on overall survival (OS)¹ and calculated 46 to 52 days as
7 threshold for decreased OS². Similar observations were reported for oral cancer in a recent
8 review including 18 studies³.

9
10 A likely reason for the association of treatment waiting time and decreased OS is meantime
11 tumour growth. Mathematical models to approximate tumour growth from imaging data are
12 available since the 1960s⁴. Originally, direct curve fitting to calculate tumour volume doubling
13 time (DT) was the standard method to assess tumour growth⁴. Recently, calculation of specific
14 growth rate (SGR), defined as relative volume increase per unit of time, was proposed instead. It
15 was reported more reliable for short time intervals and minor tumour volume differences⁵.

16
17 Data on SGR of HNSCC is limited⁶⁻⁷. A median SGR for primary tumours (PT-SGR) of 0.74% per
18 day in patients with oropharyngeal HNSCC waiting for RCT was reported by Murphy and
19 colleagues. The authors assessed the PT-SGR in 85 patients between diagnostic CTs and
20 planning CTs and concluded that rapid PT-SGR may predict treatment failure in these patients⁶.
21 Van Bockel and co-authors reported a significant association between high PT-SGR and
22 decreased OS ($p=0.013$) in 131 patients with laryngeal HNSCC⁷.

23
24 In this retrospective study, we calculated SGR⁵ of the primary tumour (PT-SGR) and largest
25 pathological cervical lymph node (LN-SGR) of patients with incident HNSCC from CTs obtained at
26 diagnosis and from planning CTs obtained directly before RT/RCT. We investigated the influence
27 of various factors including several biomarkers on PT-SGR and LN-SGR, which were previously
28 observed to be associated with tumour proliferation⁸⁻¹². We were further interested in the
29 influence of SGR on OS and on the development of new lymph node necrosis and bone or
30 cartilage infiltration.

1 MATERIALS AND METHODS

2 Tumour registry population

3 Patients referred to the Department of Otorhinolaryngology – Head and Neck Surgery, Medical
4 University of Innsbruck, Austria, between 2008 and 2016 with incident histologically confirmed
5 HNSCC were recorded in the clinical tumour registry. Disease was staged according to the
6 seventh edition of the UICC TNM staging system¹³ by an interdisciplinary tumour board.
7 Inclusion criteria comprised histologically proven incident HNSCC at any site of the head and
8 neck region including cancer of unknown primary (CUP), any UICC Stage, RT or RCT as primary
9 treatment and availability of both a diagnostic CT and a planning CT. The review board of the
10 Medical University of Innsbruck had approved the study (UN4590) and informed consent was
11 obtained from all study participants.

12 Diagnostic CT and planning CT

13 At the time of clinical diagnosis, diagnostic CT was performed following the standardized CT
14 head & neck imaging protocols at the Department of Radiology, Medical University of Innsbruck.
15 A GE-Medical Systems Light Speed VCT® or Light speed 16 CT scanner® (GE Medical, Vienna,
16 Austria) was used. The scan area ranged from the frontal sinus to the upper mediastinum with a
17 resolution of 512x512 pixels. Slices were calculated from raw data with 2 millimetres (mm)
18 thickness, collimation of 24x1.2mm and 0.45 pitch. Additional sagittal and coronal images were
19 reconstructed. As contrast medium, Jopamiro 370® (Bracco Austria GmbH, Vienna, Austria) was
20 administered intravenously adjusted to the patient's bodyweight. Planning CT scans were later
21 performed at the Department of Radiation Oncology, Medical University of Innsbruck. Imaging
22 protocols were followed as described above with the same CT scanners, contrast medium,
23 scanning areas, resolutions and calculation protocols. Images from both CT scans were exported
24 in Digital Imaging and Communications in Medicine (DICOM) format using IMPAX EE® (Agfa
25 HealthCare, Bonn, Germany) Picture Archiving and Communication System (PACS®, Cerner,
26 Kansas City USA). LN with a minimal axial diameter >10mm, a central necrosis >3mm or if
27 present in neck levels close to the primary tumour in groups of >3 were classified pathological¹⁴.

1 **Volume approximation, specific growth rate and tumour volume doubling time**

2 Volumes were calculated as previously described¹⁵. In short, maximum orthogonal diameters in
3 mm were measured for the primary tumour (PT) and the largest pathological cervical lymph (LN)
4 in all three planes in axial and coronal sections (Figure 1). Volumes in millilitres (mL) were
5 approximated employing an ellipsoid formula ($\text{volume} = (\pi * [x * y * z / 1000]) / 6$). The largest cervical
6 LN instead of all pathological cervical lymph nodes was considered sufficient for evaluation
7 based on a high correlation previously observed¹⁵. Central lymph node necrosis and/or cartilage
8 or bone infiltration of the primary tumour was recorded for additional analysis.

9
10 SGRs were assumed to be exponential and defined as the relative volume increase given in
11 percent per day. For calculation of SGR, the equation described by Mehrara and co-authors was
12 applied ($\text{SGR} = \ln[1^{\text{st}} \text{volume} * 2^{\text{nd}} \text{volume}] / [t_2 - t_1]$)⁵. For comparison with earlier studies, doubling
13 times (DT) for primary tumours (PT-DT) and for largest pathological cervical lymph nodes (LN-
14 DT) were calculated as the time difference * LN divided by the logarithm of the volume ratio of
15 the two observations¹⁶.

16 **Analysis of EGFR, Ki67 and CD44 expression**

17 Tumour biopsies were collected in 4% buffered formalin, fixed overnight and embedded using
18 the ethanol – isopropanol – wax quick 4mm protocol of Histos 5 embedding processor®
19 (Milestone, Bergamo, Italy). Five-micrometre thick paraffin sections were dewaxed and antigen
20 retrieval was performed in a Discovery automated staining system® (Ventana, Tucson, AZ, USA).
21 Primary antibodies were added to the sections by automatic dispensing either as ready-to-use,
22 pre-diluted, stabilized solutions provided by the manufacturers: cyclin dependent kinase
23 inhibitor 2A (p16) INK4® (Ventana, Cat. Nr. 6595294001), Ki67 antigen (Ki67; Linaris E059®,
24 clone MIB-1®, Dossenheim, Germany), CD44 antigen (CD44; Diagnostic Biosystems /Antibodies
25 Online, ABIN1020059, Aachen, Germany) and Epidermal Growth Factor Receptor (EGFR;
26 Invitrogen, Vienna, Austria). These three biomarkers were chosen because an association with
27 tumour proliferation had been reported⁸⁻¹²: 1) EGFR is a cell surface receptor that promotes
28 proliferation, invasion, angiogenesis and metastatic spread in HNSCC, if overexpressed⁸. Thus,
29 high expression of EGFR might suggest higher PT-SGR. 2) Ki67 is a nuclear protein expressed on
30 cells in all phases of the cell cycle except in G0-phase. Thus, its expression marks the total

1 fraction of proliferating cells in a tumour⁹⁻¹¹, which might be correlated with PT-SGR. 3) Positive
2 correlations between CD44 expression and advanced T categories were previously reported in a
3 meta-analysis including thirty studies with 2102 patients¹². Since T category is primarily based
4 on maximal tumour diameter, a possible positive correlation between CD44 expression and PT-
5 SGR was suggested. Immunohistochemical staining was completed by the Discovery automated
6 staining system[®] (Ventana, Tucson, AZ, USA) using universal secondary antibody solution,
7 haematoxylin counterstaining and the DAB MAP Kit (all Ventana products, Tucson, AZ, USA) as
8 published previously¹⁷. All sections were stained with control mouse and rabbit
9 immunoglobulins, using the same highest concentration as for the primary antibodies, and
10 these controls were not reactive¹⁸. The immunohistochemical reactions were observed
11 independently by two blinded observers, who collected 10 representative tumour cell nests
12 from each specimen¹⁹. These regions were analysed on an Olympus BX50 microscope[®]
13 (Olympus, Tokyo, Japan) and the staining intensity and representation of tumour cell nests were
14 scored as previously described²⁰. The cut-off for p16-positivity was 70% or more positive tumour
15 cells²¹.

16 **Data analysis**

17 Frequency data were presented in tabular form. For continuous data (volumes and growth
18 rates), means and standard deviations (SD) as well as medians and 25th (p25th) and 75th
19 percentiles (p75th) were provided. The median follow-up time was calculated as described by
20 Schemper and Smith²². Logarithmic transformation was used to analyse volumetric data in
21 regression models. Kruskal-Wallis and Jonckheere-Terpstra tests were used to evaluate the
22 univariate influence of ordinal factors on growth rates. For survival analyses, Kaplan Maier and
23 Cox regression models were used. For Kaplan Meier plots, growth rates were categorized in
24 groups with slow, intermediate and rapid growth rates. All calculations were performed with
25 SPSS 23.0 (IBM Corp., Armonk, NY).

27 **Patient and Public Involvement**

28 The development of the research question was based on previous publications exploring tumor
29 volume in HNSCC¹⁵ and its prognostic value if treated primarily with surgery²³. Neither patients

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 nor the public were involved in the design of the study, the recruitment of the study or the
2 conduct of the study.

For peer review only

1 RESULTS

2 Study population

3 Between 2008 and 2016, 802 patients with incident HNSCC were recorded in the clinical cancer
 4 registry. Of 123 patients treated with primary RT or RCT, PT-volumes and LN-volumes were
 5 calculated from diagnostic and planning-CTs. Tumour sites included oral cavity, oropharyngeal,
 6 hypopharyngeal and laryngeal HNSCC. No patients with tumours of the nasopharynx, the
 7 paranasal sinuses or salivary glands were included. In five patients with CUP-syndrome, no PT-
 8 volume and in 27 patients with NO neck, no LN-volume could be measured. Of the 123 patients,
 9 32 were female. The mean±SD age was 63±10 years ranging from 38 to 87 years. Median follow
 10 up time was 45 months (95% confidence interval 42 to 48 months). Additional clinical data of
 11 the 123 included patients is provided in table 1.

12 **Table 1: Clinical data of included 123 HNSCC patients.**

		No. of patients
Sex	male	89
	female	32
Age	≤ 50 years	11
	51 – 60 years	42
	61 – 70 years	39
	71 – 80 years	26
	≥ 80 years	5
p16	negative	83
	positive	38
Tumour site	oral cavity	16
	oropharynx	55
	hypopharynx	24
	larynx	21
	carcinoma of unknown primary	5
Clinical UICC stage	stage I	4
	stage II	7
	stage III	17
	stage IVa	75
	stage IVb	16
	stage IVc	2

13

1 Time interval, tumour and lymph node volumes

2 Mean±SD time interval between diagnostic CTs and planning CTs was 29±21 days ranging from 6
3 to 146 days. For PT, a total of 119 volume sets from diagnostic CT and planning CT were
4 available (Figure 2). Mean PT-volume from diagnostic CTs was 16.3±20.4mL ranging from 0
5 (CUP-syndrome) to 100.8mL. Mean PT-volume from planning CTs was 24.5±26.8mL ranging
6 from 0 to 160.3mL. The mean PT-volume increase of 6.7±17.2mL during the period between 1st
7 and 2nd CT scans was highly significant (p<0.001).

8 For LN, a total of 96 volume sets were available (Figure 2). Mean LN-volume from diagnostic CTs
9 was 9.2±22.2mL ranging from 0 (N0) to 156.2mL. Mean LN-volume from planning CTs was
10 15.2±31.5mL ranging from 0 to 233.5mL. The mean LN-volume increase of 5.3±17.3mL during
11 the observation period was highly significant (p<0.001). Distributions of these parameters were
12 right skewed. Medians and quartiles for PT-volume and LN-volume are provided in table 2.

13 **Table 2: Volumes of primary tumours and largest pathological cervical lymph nodes in**
14 **diagnostic and planning CTs in 123 patients with HNSCC. Median time interval between 1st**
15 **and 2nd CT scans was 24 days. Specific growth rates were calculated as suggested by Mehrara**
16 **and co-authors⁵, tumour doubling-times were calculated as proposed by Schwartz¹⁶.**

	Diagnostic CT volume ¹⁾ [ml]	Planning CT volume ¹⁾ [ml]	SGR ²⁾ [%/day]	DT ³⁾
Primary tumour	9.4 (3.3; 21.4)	16.7 (5.4; 31.6)	1.4 (0.6; 2.7)	43 (24; 85)
Lymph node	2.0 (0.2; 9.5;)	3.7 (0.6; 19.4)	1.2 (0.3; 2.5)	41 (25; 80)

17 1) Median (25th and 75th percentile)

18 2) Specific growth rate (median, 25th and 75th percentile) percent per day

19 3) Tumour doubling time in days (median, 25th and 75th percentile)

20

1 Specific growth rates (SGR) and tumour doubling times (DT)

2 Mean±SD PT-SGR was 1.8%±1.8%/day ranging from minus 2.6%/day (volume decrease) to
3 8.6%/day. Mean LN-SGR was 1.7%±2.0%/day ranging from minus 1.5% to 11.0%/day. PT-SGR
4 and LN-SGR were right-skewed. For medians and quartiles see table 2. Mean PT-SGR of tumours
5 of the oral cavity, oropharynx, hypopharynx and larynx were 3.1%±1.5%/day, 1.8%±1.7%/day,
6 2.0%±2.0%/day and 1.5%±2.1%/day, respectively. Mean LN-SGR for the primary tumour sites
7 oral cavity, oropharynx, hypopharynx and larynx were 3.4%±3.9%/day, 1.9%±2.2%/day,
8 1.9%±1.4%/day and 0.8%±1.1%/day, respectively. For tumour sites, medians and quartiles are
9 provided in table 3.

10 **Table 3: Specific growth rates (SGR) for primary tumours (PT) and largest pathological cervical**
11 **lymph nodes (LN) for common tumour sites of 123 patients with incident HNSCC.**

Tumour site	n	PT-SGR ¹⁾	LN-SGR ¹⁾
Oral cavity	15	2.4 (1.0; 3.9)	0.8 (0.0; 1.5)
Oropharynx	55	1.4 (0.7; 2.6)	2.5 (0.4; 2.6)
Hypopharynx	25	1.7 (0.6; 2.7)	2.1 (0.6; 2.9)
Larynx	21	1.0 (0.3; 3.1)	0.8 (0.0; 1.4)
Carcinoma of unknown primary	5	0.0 (0.0; 0.0)	1.4 (1.1; 5.2)

12 1) Median (25th and 75th percentile)

13
14 Median PT-DT was 43 days. The 25th percentile was 24 and the 75th percentile 85 days. Median
15 LN-DT was 41 days. The 25th percentile was 25 and the 75th percentile 80 days (Tab. 2). PT-DT
16 and LN-DT were considerably right skewed.

17 Factors influencing specific growth rates

18 PT-SGR was independent of the initial PT-volume in diagnostic CT (p=0.19). PT-SGR did also not
19 depend on the interval between 1st and 2nd CT (p=0.14). Moreover, tumour site had no significant
20 impact on SGR (p=0.58; Tab. 3). Interestingly, PT-SGR positively correlated with the expression of
21 EGFR, Ki67 and CD44 (p=0.02; p=0.02 and p=0.03, respectively; Figure 3). The expression of p16
22 had no influence on PT-SGR (p=0.21).

1
2
3 1 In contrast, LN-SGR depended on the initial LN-volume measured in diagnostic CT ($p=0.003$)
4 with higher LN-SGRs in lymph nodes with larger LN-volumes in the 1st CT. Also, the interval
5 2 between the diagnostic CT and planning CT significantly influenced LN-SGR ($p=0.003$). The
6 3 longer the interval, the lower the observed LN-SGR. Moreover, LN-SGR was significantly
7 4 influenced by tumour site ($p=0.032$; Tab. 3) with smallest growth rates in lymph nodes from
8 5 laryngeal HNSCC ($p=0.003$). In contrast to PT-SGR, neither EGFR, Ki67, CD44 nor p16 expression
9 6 in PTs significantly correlated with LN-SGR ($p=0.12$; $p=0.31$; $p=0.75$ and $p=0.81$, respectively).
10 7
11 8

9 **Specific-growth-rate and overall survival**

10 PT-SGR nearly missed significant impact on OS when used as a single covariate in a Cox
11 regression model (log rank $p=0.054$). For Kaplan Meier analyses, PT-SGR were categorized in 3
12 groups: slow ($< 0.3\%/day$; $n=22$); intermediate ($0.3\% \leq 3\%/day$; $n=73$) and rapid ($>3\%/day$;
13 $n=26$). Survival curves of these 3 SGR groups did not differ significantly (log rank $p=0.45$; Figure
14 4). Likewise, LN-SGR had no significant impact on OS as a covariate in Cox regression (log rank
15 $p=0.83$) nor in Kaplan Meier analyses (log rank $p=0.97$; data not shown).
16

16 **Cartilage or bone infiltration and central lymph node necrosis**

17 Cartilage or bone infiltration was observed in diagnostic CTs of 40/123 (33%) patients and in
18 planning CTs of 50/123 (41%) patients. Thus, during the median 24 days interval between the
19 two CTs, new cartilage or bone infiltration occurred in 10 patients, which was not influenced by
20 PT-SGR ($p=0.918$). However, cartilage or bone infiltration had a significant negative impact on
21 survival ($p=0.003$) and was significantly more frequent in p16 negative tumours ($p=0.02$).
22

23 Lymph node necrosis was observed in diagnostic CTs of 74/97 (76%) patients. LN-SGR was
24 significantly higher in patient with lymph node necrosis ($p<0.001$), was associated with poorer
25 survival ($p=0.03$) and did not depend on p16 status. Lymph node necrosis was observed in
26 planning CTs of 82/97 (85%) patients. Thus, during the median 24 days interval between the two
27 CTs, new lymph node necrosis occurred in 8 patients, which was not influenced by LN-SGR
28 ($p=0.818$). Central lymph node necrosis had a significant negative impact on survival ($p<0.05$).

1 DISCUSSION

2 Long waiting times for treatment of head and neck cancer result in decreased overall survival¹⁻³.

3 One reason might be meantime tumour growth. We examined tumour growth during the time
4 between the initial diagnostic CT scan and the planning CT for RT or RCT in 123 patients with
5 incident HNSCC. The majority of the patients suffered from incident stage IVa oropharyngeal
6 HNSCC.

7
8 The mean interval between 1st and 2nd CT was 29 days ranging from 6 to 146 days. In this time,
9 diagnostic work up, interdisciplinary tumour board presentation and pre-treatment procedures
10 including dental treatments and application of percutaneous gastrostomies were carried out.
11 PT- and LN-volumes in diagnostic and planning CTs were assessed using identical protocols. PT-
12 SGR and LN-SGR were calculated as proposed by Mehrara and co-authors⁵. This mean interval is
13 comparable to previously reports¹. Moreover, it is considerably shorter than intervals of 46 to
14 52 days, which were reported as threshold for decreased OS². From a clinical perspective, this is
15 considered positive. However, in terms of exploring SGR's in advanced stage HNSCC, this
16 interval may not be sufficient to accurately determine great changes in PT-volume or LN-
17 volume.

18
19 Due to the skewness of volumetric data, the median was considered an appropriate measure of
20 central tendency, but the mean is also provided for comparison with previous publications.
21 Mean PT-volume in diagnostic CTs was approximately 16mL (median≈9mL). In planning CTs of
22 the same patients 3-4 weeks later, mean PT-volume was approximately 25mL (median≈17mL;
23 Tab. 2). These PT-volumes are in line with previous publications reporting mean volumes of 11-
24 37mL²³⁻²⁶. Mean LN-volume measured in diagnostic CTs was 9mL (median≈2mL) and
25 approximately 15mL (median≈4mL) in planning CTs (Tab 2). Previously reported mean LN-
26 volumes were considerably larger with 22-25mL^{27, 28}. However, in these studies the volume of all
27 pathological cervical lymph nodes was measured instead of only the largest one as in this study.

28
29 Tumour and pathological lymph node growth can be reported as doubling time (DT) or specific
30 growth rates (SGR). DT is the number of days the tumour needs to double its volume⁴. The lower

1 the DT, the faster the tumour growth. Since DT was frequently reported in earlier studies, it was
2 provided for comparison. SGR is defined as relative increase of volume in percent per day. The
3 resulting variable is constant, linear and independent of the initially measured volumes⁵. SGR is
4 considered less affected by measurement uncertainties of short time intervals and minor volume
5 differences than DT⁵.

6
7 For both, DT and SGR, tumour volumes are required. A volume approximation method from CT
8 scans, which reflects frequently available diagnostics, was used here. This approximation was
9 based on measurements of maximum orthogonal diameters, similar to a formula described in
10 1990 by MacDonald and co-workers to approximate volumes of brain tumours²⁹. The method
11 employed an ellipsoid formula, which was applicable over a wide range of PT and LN sizes and
12 resulted only in a slight underestimation of 8% of the PT-volume measured with the reference
13 method¹⁵. A similar approximation method has also been used by Jensen and co-authors³⁰.

14 More sophisticated segmentation- and more modern imaging techniques, may have allowed for
15 better tumour margin delineation. However, they first require specific workstations with limited
16 availability¹⁵ (i.e. semi-automated or automated slice-by-slice segmentation) and large inter-
17 observer variations may remain³¹. The latter may allow better visualisation of oropharyngeal and
18 oral HNSCC (i.e. magnetic resonance imaging MRI) or better visualisation of locally advanced
19 tumours (i.e. fluorodesoxyglucose positron emission tomography FDG-PET). However, both
20 imaging techniques are not as frequently available as CT scans and other limitations apply. For
21 MRIs blurred tumour margins may be observed if patients swallow or breathe, for FDG-PET a lack
22 of spatial resolution may be disadvantageous in smaller HNSCC tumours³¹.

23
24 Mean primary tumour specific growth rates (PT-SGR) in incident HNSCC was 1.8%/day (Tab. 2),
25 unimodally distributed, slightly right skewed and independent of the initial PT-volume, which
26 supports the basic concept underlying SGR calculation. The interval between diagnostic CT and
27 planning CT did not influence PT-SGR ($p=0.1$), suggesting that no marked growth deceleration
28 occurred with longer waiting times. Interestingly, PT-SGRs did not significantly differ by tumour
29 site ($p=0.6$; Tab 3). Murphy and colleagues observed a lower median SGR of 0.74%/day in patients
30 with oropharyngeal cancer⁶. However, the authors did not include sites with faster tumour

1 growth such as the oral cavity (median SGR 2.4%/day) and hypopharynx (median SGR 2.0%/day).
 2 Moreover, most of the patients reported by Murphy and colleagues had T1 or T2 HNSCC and were
 3 p16 positive.

4
 5 The median PT-DT in this study was 43 days. The 25th percentile was 24 and the 75th percentile 85
 6 days. Median LN-DT was 41 days. The 25th percentile was 25 and the 75th percentile 80 days (Tab.
 7 2). Jensen and co-authors reported a slower growth rate in 61 patients with HNSCC with a median
 8 PT-DT of 99 days. The authors however additionally stated that half of the patients showed a
 9 faster growth rate with a PT-DT of 30 days³⁰. When compared with DT of other solid tumours, this
 10 means that HNSCC reveal rapid tumour growth. For breast cancer, Ingebly and co-authors
 11 reported a median DT of 285 days⁴. For lung cancer, DTs vary depending on histology between
 12 median 42 days for metastases as reported by Loeffler and colleagues and 181 for non-small-
 13 cellular lung cancer as reported by Winer-Muram and co-workers^{4,32}. For pancreatic
 14 adenocarcinoma, Furkawa and colleagues reported a mean PT-DT of 144 days³². For Sarcomas
 15 median PT-DTs of 35 days were reported by Blomqvist and co-authors³². Additional median PT-
 16 DTs for additional solid tumours are provided in table 4.

17
 18 **Table 4: Reported tumour volume doubling times for selected solid tumours*.**

Tumour	Median DT [days]	n
Present study	47	123
HNSCC ³⁰	99**	61
Breast cancer ⁴	285	16
Lung bronchioalveolarcarcinoma ³²	181	9
Non small-cell lung carcinoma ³²	181	6
Lung metastasis ⁴	42	24
Pancreatic adenocarcinoma ³²	144	9
Sarcoma ³²	35	21

1
2
3 1 *modified after Mehrara and co-authors³²

4
5 2 **Jensen and co-workers also stated tumour volume doubling times for the faster growing half
6
7 3 of the patients with a median PT-DT of 30³⁰.

8
9 4
10 5 PT-SGRs significantly correlated with the expression of EGFR, Ki67 and CD44 (p=0.021; p=0.018
11 6 and p=0.031, respectively) with higher PT-SGRs in patients with higher expression of the three
12 7 biomarkers (Figure 3). These correlations appear biologically sound. A correlation of clinical
13
14 8 tumour growth rates and expression of these biomarkers within the tumour of the same patients
15
16 9 was not yet reported. EGFR is a cell surface receptor which promotes proliferation, invasion,
17
18 10 angiogenesis and metastatic spread in HNSCC, if overexpressed⁸. Ki-67 is a nuclear protein
19
20 11 expressed on cells in all phases of the cell cycle except in G0-phase. Thus, its expression marks
21
22 12 the total fraction of proliferating cells in a tumour⁹. In laryngeal and hypopharyngeal SCC, an
23
24 13 association between Ki67 expression and advanced tumour stages has been reported¹⁰⁻¹¹. In line
25
26 14 with our observation of a correlation of CD44 expression and PT-SGR, an association between
27
28 15 advanced T categories and high CD44 expressions has been reported in a meta-analysis including
29
30 16 thirty studies with 2102 patients¹². No significant correlation between PT-SGR and p16 expression
31
32 17 was observed (p=0.81). This observation differs from previous observations made by Murphy and
33
34 18 colleagues. The authors observed that p16 expression correlated well with PT-SGR with faster
35
36 19 growth rates in p16 negative HNSCCs. However, the authors included oropharyngeal HNSCC only
37
38 20 and the majority (79%) were p16 positive tumours⁶. When used as a covariate in a Cox model, PT-
39
40 21 SGR had no significant effect on OS (log rank p=0.054). No significant differences of survival curves
41
42 22 were also observed, if PT-SGR were categorized in groups of low, medium and high growth rates
43
44 23 (log rank p=0.45; Figure 4). In contrast, van Bockel and co-worker observed a significant
45
46 24 association between PT-SGR and OS in laryngeal cancer⁷.

47 25
48
49 26 To our knowledge, no data on lymph node specific growth rates (LN-SGR) in HNSCC have been
50
51 27 previously reported. In the investigated patients, the mean LN-SGR was 1.7%/day, similar to mean
52
53 28 PT-SGR (Tab. 2). In contrast to PT-SGR, LN-SGR did depend on initial LN-volumes in diagnostic CT
54
55 29 scans (p=0.003) with higher LN-SGRs in lymph nodes with larger initial LN-volumes. Also, the
56
57 30 interval between diagnostic CT and planning CT significantly influenced LN-SGR (p=0.003). The

1 longer the interval, the lower the observed LN-SGR, suggesting growth slowdown. Moreover, LN-
2 SGR was significantly influenced by tumour site ($p=0.03$; Tab. 3), with smallest growth rates in
3 lymph nodes from laryngeal HNSCC. In contrast to PT-SGR, LN-SGR did not depend on expressions
4 of EGFR, Ki67, CD44 nor p16 expression in primary tumours ($p=0.115$; $p=0.311$; $p=0.746$ and
5 $p=0.809$ respectively). In LN, specific growth rates had no significant impact on OS either ($p>0.05$).
6

7 New cartilage or bone infiltrations during the observation period were observed in 10 patients
8 and new central lymph node necroses were observed 8 patients. Specific growth rates had no
9 significant impact on the development of either of them. Both, initial cartilage or bone infiltration
10 and central lymph node necrosis were associated with worse survival. However, probably due to
11 the low number of events, no significant impact of new cartilage or bone infiltration nor new
12 central lymph node necrosis on survival was observed in Kaplan Meier analysis (both log rank
13 $p>0.05$).
14

15 Some limitations of the present study need to be addressed. Firstly, this small numbered
16 retrospective study predominantly exploring patients with advanced stage oropharyngeal HNSCC
17 should be supplemented by a larger, prospective investigation, which also included patients with
18 limited disease of all common HNSCC tumour sites. Secondly, the approximation method¹⁵
19 proposed here may be easily performed from frequently available CT scans over a wide range of
20 different PT- and LN-volumes. However, more sophisticated segmentation- and more modern
21 imaging techniques may have allowed for better tumour margin delineation and hence for more
22 accurate SGRs. Thirdly, the comparably short interval between diagnostic CT scans and planning
23 CT scans may be considered positive from a clinical perspective. However, in terms of exploring
24 SGRs in advanced stage HNSCC, this interval may not be sufficient to accurately determine great
25 changes in PT- and LN-volume.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **CONCLUSION**

2 Head and neck squamous cell carcinomas are rapidly growing malignancies. Primary tumours
3 and lymph nodes grow more than 1% per day. Consequently, time matters, and treatment must
4 not be delayed.

For peer review only

1 ABBREVIATIONS

2	1	CD44	CD44 antigen
3	2	CT	computed tomography
4	3	DICOM	Digital Imaging and Communications in Medicine
5	4	DT	tumour volume doubling time
6	5	EGFR	epidermal growth factor receptor
7	6	FDG-PET	fluorodesoxyglucose positron emission tomography
8	7	HNSCC	head and neck squamous cell carcinoma
9	8	Ki67	Ki67 antigen
10	9	LN	largest pathological cervical lymph node
11	10	LN-DT	largest pathological cervical lymph node doubling time
12	11	LN-SGR	largest pathological cervical lymph node specific growth rate
13	12	MRI	magnetic resonance imaging
14	13	p16	Cyclin-dependent kinase inhibitor 2A
15	14	PACS	Picture Archiving and Communication System
16	15	PT	primary tumour
17	16	PT-DT	primary tumour volume doubling time
18	17	PT-SGR	primary tumour specific growth rate
19	18	RCT	radiochemotherapy
20	19	RT	radiotherapy
21	20	SD	standard deviation
22	21	SGR	specific growth rate
23	22	TNM	tumour, node, metastasis
24	23	UICC	Union internationale contre le cancer

1 **REQUIRED STATEMENTS**

2 **Acknowledgements**

3 This work has not yet been previously presented at a conference or as a conference abstract.

4 **Copyright statement**

5 The Corresponding Author has the right to grant on behalf of all authors and does grant on
6 behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd
7 to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL
8 products and sublicenses such use and exploit all subsidiary rights, as set out in our licence.

10 **Ethics statement**

11 The review board of the Medical University of Innsbruck had approved the study (UN4590) and
12 informed consent was obtained from all study participants. All procedures performed in studies
13 involving human participants were in accordance with the ethical standards of the institutional
14 review board and with the 1964 Helsinki declaration and its later amendments or comparable
15 ethical standards.

16 **Competing interest and funding statement**

17 All authors have completed the Unified Competing Interest form and declare: no support from
18 any organisation for the submitted work; no financial relationships with any organisations that
19 might have an interest in the submitted work in the previous three years, no other relationships
20 or activities that could appear to have influenced the submitted work.

21 **Contributorship statement**

22 Daniel Dejaco has written major parts of the manuscript and performed the calculations of
23 tumour and lymph node volumes. Teresa Steinbichler was involved in establishing the study
24 concept, design and the internal review process of the manuscript. Schartinger Volker
25 established the population based tumour registry from which patients were enrolled. He further
26 obtained the ethics committee approval for the study. Natalie Fischer performed additional
27 tumor and pathological cervical lymph node measurements and was involved in the internal

1 review process of the manuscript. Maria Anegg has performed additional calculations and data
2 base work in the population based tumour registry. Jozef Dudas performed the
3 immunohistochemical staining of the tumour biopsies and was involved in establishing the
4 study concept, design and the internal review process of the manuscript. Andrea Posch
5 provided the radiotherapy-planning CT scans and performed performed additional tumor and
6 pathological cervical lymph node measurements. Gerlig Widmann supervised the tumor and
7 pathological cervical lymph node measurements as an experienced head and neck radiologist.
8 Herbert Riechelmann supervised the writing process of the manuscript and performed all
9 statistical calculations in the manuscript.

10 **Transparency declaration**

11 The Corresponding Author affirms that the manuscript is an honest, accurate, and transparent
12 account of the study being reported; that no important aspects of the study have been omitted;
13 and that any discrepancies from the study have been explained.

14 **Details of ethical approval and patient consent**

15 The review board of the Medical University of Innsbruck had approved the study (UN4590) and
16 informed consent was obtained from all study participants.

17 **Data sharing**

18 No additional data from the study is available.

1 REFERENCES

- 1 1. Murphy CT, Galloway TJ, Handorf EA, et al. Increasing time to treatment initiation for head
2 and neck cancer: an analysis of the National Cancer Database. *Cancer* 2015;121(8):1204-13. doi:
3 10.1002/cncr.29191 [published Online First: 2014/12/11]
- 4 2. Murphy CT, Galloway TJ, Handorf EA, et al. Survival Impact of Increasing Time to Treatment
5 Initiation for Patients With Head and Neck Cancer in the United States. *J Clin Oncol*
6 2016;34(2):169-78. doi: 10.1200/jco.2015.61.5906 [published Online First: 2015/12/03]
- 7 3. Stefanuto P, Doucet JC, Robertson C. Delays in treatment of oral cancer: a review of the
8 current literature. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2014;117(4):424-9. doi:
9 10.1016/j.oooo.2013.12.407 [published Online First: 2014/02/22]
- 10 4. Steel GG, Lamerton LF. The growth rate of human tumours. *Br J Cancer* 1966;20(1):74-86.
11 [published Online First: 1966/03/01]
- 12 5. Mehrara E, Forssell-Aronsson E, Ahlman H, et al. Specific growth rate versus doubling time for
13 quantitative characterization of tumor growth rate. *Cancer Res* 2007;67(8):3970-5. doi:
14 10.1158/0008-5472.can-06-3822 [published Online First: 2007/04/19]
- 15 6. Murphy CT, Devarajan K, Wang LS, et al. Pre-treatment tumor-specific growth rate as a
16 temporal biomarker that predicts treatment failure and improves risk stratification for
17 oropharyngeal cancer. *Oral Oncol* 2015;51(11):1034-40. doi:
18 10.1016/j.oraloncology.2015.09.001 [published Online First: 2015/09/28]
- 19 7. van Bockel LW, Verduijn GM, Monninkhof EM, et al. The importance of actual tumor growth
20 rate on disease free survival and overall survival in laryngeal squamous cell carcinoma.
21 *Radiother Oncol* 2014;112(1):119-24. doi: 10.1016/j.radonc.2014.06.004 [published Online First:
22 2014/07/06]
- 23 8. Bossi P, Resteghini C, Paielli N, et al. Prognostic and predictive value of EGFR in head and neck
24 squamous cell carcinoma. *Oncotarget* 2016;7(45):74362-79. doi: 10.18632/oncotarget.11413
25 [published Online First: 2016/08/25]
- 26 9. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol*
27 2000;182(3):311-22. doi: 10.1002/(sici)1097-4652(200003)182:3<311::Aid-jcp1>3.0.Co;2-9
28 [published Online First: 2000/02/01]

- 1
2
3 1 10. Ashraf MJ, Maghbul M, Azarpira N, et al. Expression of Ki67 and P53 in primary squamous
4 cell carcinoma of the larynx. *Indian J Pathol Microbiol* 2010;53(4):661-5. doi: 10.4103/0377-
5 2 4929.72019 [published Online First: 2010/11/04]
6 3
7 4 11. Wang JX, Zhang YY, Yu XM, et al. Role of centromere protein H and Ki67 in relapse-free
8 survival of patients after primary surgery for hypopharyngeal cancer. *Asian Pac J Cancer Prev*
9 5 2012;13(3):821-5. [published Online First: 2012/05/29]
10 6
11 7 12. Chen J, Zhou J, Lu J, et al. Significance of CD44 expression in head and neck cancer: a
12 systemic review and meta-analysis. *BMC Cancer* 2014;14:15. doi: 10.1186/1471-2407-14-15
13 8
14 9 [published Online First: 2014/01/15]
15 10
16 11 13. Sobin L WC. *TNM Classification of Malignant Tumours*: Wiley-Blackwell 2009.
17 12
18 13 14. van den Brekel MW, Stel HV, Castelijns JA, et al. Cervical lymph node metastasis: assessment
19 of radiologic criteria. *Radiology* 1990;177(2):379-84. doi: 10.1148/radiology.177.2.2217772
20 11
21 12 [published Online First: 1990/11/01]
22 13
23 14 15. Dejaco D, Url C, Schartinger VH, et al. Approximation of head and neck cancer volumes in
24 contrast enhanced CT. *Cancer Imaging* 2015;15:16. doi: 10.1186/s40644-015-0051-3 [published
25 16
26 Online First: 2015/10/01]
27 17
28 18 16. Schwartz M. A biomathematical approach to clinical tumor growth. *Cancer* 1961;14:1272-94.
29 15
30 17 [published Online First: 1961/11/01]
31 18
32 19 17. Dudas J, Schartinger VH, Romani A, et al. Cell cycle association and hypoxia regulation of
33 excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck
34 20
35 21 cancer. *Tumour Biol* 2014;35(8):7807-19. doi: 10.1007/s13277-014-2001-2 [published Online
36 22
37 First: 2014/05/13]
38 23
39 24 18. Schartinger VH, Falkeis C, Laimer K, et al. Neuroendocrine differentiation in head and neck
40 21
41 22 squamous cell carcinoma. *J Laryngol Otol* 2012;126(12):1261-70. doi:
42 23
43 24 10.1017/S0022215112002265
44 25
45 26 19. Rietbergen MM, Snijders PJ, Beekzada D, et al. Molecular characterization of p16-
46 27
47 28 immunopositive but HPV DNA-negative oropharyngeal carcinomas. *Int J Cancer*
48 2014;134(10):2366-72. doi: 10.1002/ijc.28580 [published Online First: 2013/11/20]
49 26
50 27
51 28
52
53
54
55
56
57
58
59
60

- 1
2
3 1 20. Smilek P, Dusek L, Vesely K, et al. Correlation of expression of Ki-67, EGFR, c-erbB-2, MMP-9,
4 p53, bcl-2, CD34 and cell cycle analysis with survival in head and neck squamous cell cancer. J
5 Exp Clin Cancer Res 2006;25(4):549-55. [published Online First: 2007/02/22]
6
7 21. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR
8 expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007;120(8):1731-8. doi:
9 10.1002/ijc.22355 [published Online First: 2007/01/20]
10
11 22. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control
12 Clin Trials 1996;17(4):343-6. [published Online First: 1996/08/01]
13
14 23. Dejaco D, Steinbichler T, Schartinger VH, et al. Prognostic value of tumor volume in patients
15 with head and neck squamous cell carcinoma treated with primary surgery. Head Neck
16 2018;40(4):728-39. doi: 10.1002/hed.25040 [published Online First: 2017/12/23]
17
18 24. Davis KS, Lim CM, Clump DA, et al. Tumor volume as a predictor of survival in human
19 papillomavirus-positive oropharyngeal cancer. Head Neck 2016;38 Suppl 1:E1613-7. doi:
20 10.1002/hed.24287 [published Online First: 2015/12/19]
21
22 25. Kneijens JL, Hauptmann M, Pameijer FA, et al. Tumor volume as prognostic factor in
23 chemoradiation for advanced head and neck cancer. Head Neck 2011;33(3):375-82. doi:
24 10.1002/hed.21459 [published Online First: 2010/07/16]
25
26 26. Oemus D, Inhestern J, Schmalenberg H, et al. Prognostic value of tumor volumetry data of
27 routine imaging data in a head and neck cancer registry. Eur Arch Otorhinolaryngol
28 2014;271(9):2531-7. doi: 10.1007/s00405-013-2800-x [published Online First: 2013/11/07]
29
30 27. Chen SW, Yang SN, Liang JA, et al. Prognostic impact of tumor volume in patients with stage
31 III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent
32 chemoradiotherapy. Head Neck 2009;31(6):709-16. doi: 10.1002/hed.21011 [published Online
33 First: 2009/03/05]
34
35 28. Doweck I, Denys D, Robbins KT. Tumor volume predicts outcome for advanced head and
36 neck cancer treated with targeted chemoradiotherapy. Laryngoscope 2002;112(10):1742-9. doi:
37 10.1097/00005537-200210000-00006 [published Online First: 2002/10/09]
38
39 29. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG. Response criteria
40 for phase II studies of supratentorial malignant glioma. J Clin Oncol.1990;8:1277-80. doi:
41 10.1200/JCO.1990.8.7.1277.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 30. Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy
4 2 in head and neck cancer. *Radiother Oncol* 2007;84(1):5-10.
- 5 31. Grégoire V, Evans M, Le QT, et al. Delineation of the primary tumour Clinical Target Volumes
6 4 (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma:
7 5 AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC
8 6 CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus
9 7 guidelines. *Radiother Oncol*. 2018 Jan;126(1):3-24. doi: 10.1016/j.radonc.2017.10.016 [published
10 8 Online First: 2017/11/24]
- 11 32. Mehrara E, Forssell-Aronsson E, Ahlman H, et al. Quantitative analysis of tumor growth rate
12 9 and changes in tumor marker level: specific growth rate versus doubling time. *Acta Oncol*
13 10 2009;48(4):591-7. doi: 10.1080/02841860802616736 [published Online First: 2009/03/31]
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 FIGURE LEGENDS**
4

5
6 **2 Figure 1: Tumour growth assessment using maximal orthogonal tumour diameters from axial**
7
8 **3 contrast enhanced diagnostic CT scans (A) and subsequent planning CT scans (B)**

9
10 4 Axial contrast enhanced diagnostic CT scan (A) and subsequent planning CT scan (B) 46 days
11
12 5 later of a cT4a cN2b cM0 squamous cell carcinoma of the oral cavity. The maximum anterior-
13
14 6 posterior and medio-lateral tumour diameters (white lines) were measured from axial scans, the
15
16 7 cranio-caudal tumour diameters were measured from corresponding coronal scans (not
17
18 8 depicted). The tumour volume was assessed as previously described using an ellipsoid
19
20 9 formula¹⁵. PT-volume from diagnostic CT was 14.8mL, PT-volume from planning CT was 51.0mL
21
22 10 translating to a PT-SGR of 2.8%/day.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 Figure 2: Correlation of primary tumour volume (A) and largest pathological lymph node**
4 **2 volume (B) measured from diagnostic CT scans and a planning CT scans**

5
6
7 3 Scattergram of primary tumour volumes (A) and largest pathological lymph node volume (B)
8
9 4 measured from diagnostic CT scans (x-axis) planning CT scans (y-axis). Both axes are on log scale.
10
11 5 The diagonal line represents the line of identity. Dots above this line indicate volume increases.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 Figure 3: Specific growth rates of the primary tumours and percentage of Ki67 positive cells**
4
5 2 Percentage of Ki67 positive immunohistochemistry in tumour samples of HNSCC patients and
6
7 3 according primary tumour specific growth rates. The percentage of Ki67 positive cells was
8
9 4 grouped in 0%, 1 to 30%, 31 to 60% and more than 60% of cancer cells (x-axis). Mean specific
10
11 5 growth rates of HNSCC primary tumour (y-axis) were obtained 119 patients. Small bars
12
13 6 represent standard deviation. PT-SGR positively correlated with the expression of Ki67
14
15 7 (Jonckheere-Terpstra $p=0.02$).
16
17 8

1
2
3 **1 Figure 4: Kaplan Maier plot for specific growth rates of primary tumours grouped by low,**
4 **2 medium and high growth rate**

5
6
7 3 Kaplan Maier plot of specific growth rates (SGR) of primary tumours grouped by low (black line;
8 4 $SGR < 0.3\%/day$; $n=22$); medium (dark grey line; $0.3\% \leq SGR < 3\%/day$; $n=73$) and high (pale grey
9 5 line; $SGR > 3\%/day$; $n=26$) growth rates. X-axis represents time in months, Y-axis overall survival.
10
11
12 6 The survival curves of the 3 specific growth rate groups did not differ significantly (log rank
13
14 7 $p=0.45$).
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Tumour growth assessment using maximal orthogonal tumour diameters from axial contrast enhanced diagnostic CT scans (A) and subsequent planning CT scans (B) Axial contrast enhanced diagnostic CT scan (A) and subsequent planning CT scan (B) 46 days later of a cT4a cN2b cM0 squamous cell carcinoma of the oral cavity. The maximum anterior-posterior and medio-lateral tumour diameters (white lines) were measured from axial scans, the cranio-caudal tumour diameters were measured from corresponding coronal scans (not depicted). The tumour volume was assessed as previously described using an ellipsoid formula⁹. PT-volume from diagnostic CT was 14.8mL, PT-volume from planning CT was 51.0mL translating to a PT-SGR of 2.8%/day.

11x7mm (600 x 600 DPI)




Figure 2: Correlation of primary tumour volume (A) and largest pathological lymph node volume (B) measured from diagnostic CT scans and a planning CT scans
Scattergram of primary tumour volumes (A) and largest pathological lymph node volume (B) measured from diagnostic CT scans (x-axis) planning CT scans (y-axis). Both axes are on log scale. The diagonal line represents the line of identity. Dots above this line indicate volume increases.

16x7mm (600 x 600 DPI)




Figure 3: Specific growth rates of the primary tumours and percentage of Ki67 positive cells
Percentage of Ki67 positive immunohistochemistry in tumour samples of HNSCC patients and according primary tumour specific growth rates. The percentage of Ki67 positive cells was grouped in 0%, 1 to 30%, 31 to 60% and more than 60% of cancer cells (x-axis). Mean specific growth rates of HNSCC primary tumour (y-axis) were obtained 119 patients. Small bars represent standard deviation. PT-SGR positively correlated with the expression of Ki67 (Jonckheere-Terpstra $p=0.02$).

16x14mm (600 x 600 DPI)




Figure 4: Kaplan Maier plot for specific growth rates of primary tumours grouped by low, medium and high growth rate

Kaplan Maier plot of specific growth rates (SGR) of primary tumours grouped by low (black line; $\text{SGR} < 0.3\%/ \text{day}$; $n=22$); medium (dark grey line; $0.3\% \leq \text{SGR} < 3\%/ \text{day}$; $n=73$) and high (pale grey line; $\text{SGR} > 3\%/ \text{day}$; $n=26$) growth rates. X-axis represents time in months, Y-axis overall survival. The survival curves of the 3 specific growth rate groups did not differ significantly (log rank $p=0.45$).

16x14mm (600 x 600 DPI)

STROBE Statement: “Time matters – the fast growth of head and neck squamous cell carcinoma”

	Item No	Answer
Title and abstract	1	(a) The retrospective study design was described in the “Abstract” section, page 2, line 7, the “Strengths and Limitations of the Study” section, page 3 and the “Introduction” section, page 5. (b) An informative and balanced summary of what was done was provided in the “Abstract” section, page 2.
Introduction		
Background/rationale	2	The scientific background and rationale for the investigation was reported in the “Introduction” section of the manuscript, page 5.
Objectives	3	The objective of the study was specified in the “Abstract” section, page 2 and at the end of the “Introduction” section, page 2.
Methods		
Study design	4	Key elements of the study design were mentioned early in the “Abstract” section, page 2 and the “Introduction” section, page 5 of the manuscript. Additional details of the study design were outlined in the “Methods”, page 6 to 8.
Setting	5	The setting, location, relevant dates, including period of recruitment and data collection was included in the “Methods” section, page 6 and in the “Results” section, page 9.
Participants	6	(a) <i>Cohort study</i> — The eligibility criteria and the sources and methods of selection of participants are provided in detail in the “Methods” section, page 6. (b) <i>Cohort study</i> — No matching was performed in this study.
Variables	7	All outcomes, predictors, potential confounders and effect modifiers were defined, presented and discussed in the “Methods” section, page 6 to 8, “Results” section, page 9 to 12 and “Discussion” section, page 13 to 16. Diagnostic criteria were provided in the “Methods” section, page 6, when applicable.
Data sources/ measurement	8*	Source of data and details of methods was provided in the “Methods” section, page 6 and 8.
Bias	9	Potential sources of bias were addressed in the “Discussion” section, page 13 to 16.
Study size	10	An explanation how the study size was arrived at was provided in the “Method” section, page 6.
Quantitative variables	11	An explanation how quantitative variables were handled in the analyses was provided in the “Methods” section, page 8.
Statistical methods	12	(a) All statistical methods were described in the “Methods” section, page 8. (b) All methods for subgroup analyses of the presented study were described in the “Methods” section, page 8. (c) An explanation how missing data was addressed was provided in the “Methods” section, page 8, “Results” section, pages 9 to 12 and “Discussion” section, pages 13 to 16. (d) <i>Cohort study</i> —No loss to follow-up occurred due to the study design. (e) No sensitivity analyses were performed in the study.

Continued on next page

Results		
Participants	13*	(a) Numbers of individuals at each stage of the study was reported in the “Results” section, page 9 and the “Discussion” section, page 13. (b) No non-participation occurred due to the study design. (c) No flow diagram was used for this study.
Descriptive data	14*	(a) Clinical characteristics of study participants were provided in table 1, page 9. (b) Number of participants with missing data for each variable of interest was provided in the “Results” section, page 9 and in table 1, page 9. (c) <i>Cohort study</i> —Follow-up time was summarised as time between diagnostic computed tomography scan and planning computed tomography scan in this study provided in the “Results” section, page 9.
Outcome data	15*	<i>Cohort study</i> — Numbers of outcome events was provided in the “Results” section, page 9 to 12.
Main results	16	(a) Means, medians, standard deviations, 95% confidence intervals and 25 th and 75 th percentiles were provided in the “Results” section, page 9 to 12, if applicable. (b) Category boundaries for continuous variables were specified in the “Methods” section, page 8 and “Results” section, pages 9 to 12. (c) No relative risk estimations were performed in this study.
Other analyses	17	All additional other analyses performed in the study were outlined in the “Methods” section, page 8 and “Results” section, pages 9 to 12.
Discussion		
Key results	18	Key results with reference to previously outlined study objectives were summarised in the “Discussion” section, pages 13 to 16.
Limitations	19	Limitations of the study, taking into account sources of potential bias and imprecision were outlined in the “Discussion” section, pages 13 to 16.
Interpretation	20	A cautious overall interpretation of the results was given in the “Discussion”, pages 13 to 16 and the “Conclusion” section, page 17.
Generalisability	21	The external validity of the study results was outlined in the “Discussion” section, pages 13 to 16 and table 4, page 15.
Other information		
Funding	22	No financial support for any of the work presented in the present manuscript was obtained, provided on page 19.

BMJ Open

Specific growth rates calculated from computed tomographies in patients with head and neck squamous cell carcinoma: a retrospective study performed in Austria

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025359.R2
Article Type:	Research
Date Submitted by the Author:	19-Dec-2018
Complete List of Authors:	Dejaco, Daniel; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Steinbichler, Teresa; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Schartinger, Volker; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Fischer, Natalie; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Anegg, Maria; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Dudas, Jozsef; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery Posch, Andrea; Medical University of Innsbruck, Department of Radiationoncology Widmann, Gerlig; Medizinische Universitat Innsbruck, Department of Radiology Riechelmann, Herbert; Medical University of Innsbruck, Department of Otorhinolaryngology – Head and Neck Surgery
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Ear, nose and throat/otolaryngology, Diagnostics, Radiology and imaging
Keywords:	head and neck squamous cell carcinoma, tumour volume, tumour growth rate, EGFR, Ki67, CD44

SCHOLARONE™
Manuscripts

1
2
3 **1 Specific growth rates calculated from computed tomographies in patients with head**
4 **2 and neck squamous cell carcinoma: a retrospective study performed in Austria**
5
6
7
8
9
10
11
12
13
14

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4 Dejaco D^{a,§} – Steinbichler T^a – Schartinger VH^a – Fischer N^a – Anegg M^a – Dudas J^a – Posch A^b –
5 Widmann G^c – Riechelmann H^a

6
7 ^aDepartment of Otorhinolaryngology – Head and Neck Surgery, Medical University of Innsbruck,
8 Anichstr. 35, 6020 Innsbruck, Austria

9 ^bDepartment of Radiationoncology, Medical University of Innsbruck, Anichstr. 35, 6020
10 Innsbruck, Austria

11 ^cDepartment of Radiology, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck,
12 Austria

13
14 [§]Corresponding author:

15 Dejaco Daniel, MD

16 Department of Otorhinolaryngology – Head and Neck Surgery, Medical University of Innsbruck
17 Anichstr. 35, 6020 Innsbruck, Austria

18 Tel.: +43 512 504 23140 Fax: +43 512 504 23144 E-Mail: daniel.dejaco@i-med.ac.at

19
20 Word count: 3848

21 Abstract: 238

22 References: 32

23 Figures: 4

24 Tables: 4
25

1
2
3
4 1 **ABSTRACT**

5
6 2 **OBJECTIVE:** To provide data on specific growth rates (SGR) of primary tumours (PT-SGR) and
7
8 3 largest pathological cervical lymph nodes (LN-SGR) for head and neck squamous cell carcinoma
9
10 4 (HNSCC). To explore PT-SGR's and LN-SGR's correlation with selected biomarkers EGFR, Ki67 and
11
12 5 CD44.

13 6 **DESIGN AND SETTING:** Retrospective study performed at a tertiary oncologic referral centre in
14
15 7 Innsbruck, Austria.

16
17 8 **PARTICIPANTS:** Adult patients with incident HNSCC treated with primary radiotherapy (RT) or
18
19 9 radiochemotherapy (RCT).

20
21 10 **OUTCOME MEASURES:** Volumes of the primary tumour (PT-volume) and largest pathological
22
23 11 cervical lymph node (LN-volume) were measured in computed tomography (CT) scans obtained
24
25 12 at time of diagnosis and subsequent planning CTs immediately prior to RT or RCT. SGRs were
26
27 13 calculated assuming an exponential growth function. PT-SGR's and LN-SGR's correlation with
28
29 14 EGFR, Ki67 and CD44 were explored.

30
31 15 **RESULTS:** In 123 patients, mean interval between diagnostic and planning CT was 29±21 days.
32
33 16 PT-SGR was 1.8%±1.8% (mean±SD) per day and was positively correlated with EGFR, Ki67 and
34
35 17 CD44 expression (p=0.02; p=0.02; p=0.03). LN-SGR was 1.7%±2.0% per day and increased with
36
37 18 larger initial LN-volume, was lower in laryngeal cancer (p=0.003) and slowed down with time.
38
39 19 LN-SGR was not correlated with EGFR, Ki67 or CD44 expression in primary tumours (p>0.12).
40
41 20 New cartilage or bone infiltration occurred in 10 patients and new central lymph node necrosis
42
43 21 in 8 patients.

44
45 22 **CONCLUSIONS:** HNSCC are fast growing tumours for which treatment must not be delayed.
46
47 23 Clinical tumour growth rates are influenced by EGFR, Ki67 and CD44 expression.
48
49
50
51
52
53
54
55
56
57
58
59
60

1 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 2 • In patients with incident head and neck squamous cell carcinoma (HNSCC), specific
3 growth rates (SGR) for primary tumours (PT) and largest pathological cervical lymph
4 nodes (LN) were retrospectively calculated.
- 5 • SGR in percentage growth per day was calculated from two CT scans obtained at time of
6 diagnosis and subsequent planning CTs immediately prior to radiochemotherapy as
7 previously described ($SGR = \ln[1^{st} \text{volume} * 2^{nd} \text{volume}] / [t_2 - t_1]$).
- 8 • Volumes in millilitres (mL) for PT and LN were calculated from maximum orthogonal
9 diameters in all three planes applying an ellipsoid formula as previously described
10 ($\text{volume} = (\pi * [x * y * z / 1000]) / 6$).
- 11 • To explore the impact of SGR of PT and LN on overall survival, Kaplan Maier and Cox
12 regression models were used, to explore the correlation of SGR with EGFR, Ki67 and
13 CD44, Jonckheere-Terpstra tests were used.
- 14 • Limitations include retrospective study design, small number of patients, small interval
15 of observation, lack of more modern imaging- and segmentation techniques.

1
2
3
4 **1 KEYWORDS**

5
6 2 head and neck squamous cell carcinoma; tumour volume; tumour growth rate; EGFR; Ki67;

7
8 3 CD44;
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTRODUCTION

2 In patients with head and neck squamous cell carcinoma (HNSCC), the median treatment
3 waiting time in the US almost doubled from 19 to 30 days between 1998 and 2011. In a recent
4 cancer registry based study, Murphy and co-authors analysed almost 275.000 patients with
5 HNSCC of the most common cancer sites. The authors observed an independent effect of
6 increased treatment waiting time on overall survival (OS)¹ and calculated 46 to 52 days as
7 threshold for decreased OS². Similar observations were reported for oral cancer in a recent
8 review including 18 studies³.

9
10 A likely reason for the association of treatment waiting time and decreased OS is meantime
11 tumour growth. Mathematical models to approximate tumour growth from imaging data are
12 available since the 1960s⁴. Originally, direct curve fitting to calculate tumour volume doubling
13 time (DT) was the standard method to assess tumour growth⁴. Recently, calculation of specific
14 growth rate (SGR), defined as relative volume increase per unit of time, was proposed instead. It
15 was reported more reliable for short time intervals and minor tumour volume differences⁵.

16
17 Data on SGR of HNSCC is limited⁶⁻⁷. A median SGR for primary tumours (PT-SGR) of 0.74% per
18 day in patients with oropharyngeal HNSCC waiting for RCT was reported by Murphy and
19 colleagues. The authors assessed the PT-SGR in 85 patients between diagnostic CTs and
20 planning CTs and concluded that rapid PT-SGR may predict treatment failure in these patients⁶.
21 Van Bockel and co-authors reported a significant association between high PT-SGR and
22 decreased OS (p=0.013) in 131 patients with laryngeal HNSCC⁷.

23
24 In this retrospective study, we calculated SGR⁵ of the primary tumour (PT-SGR) and largest
25 pathological cervical lymph node (LN-SGR) of patients with incident HNSCC from CTs obtained at
26 diagnosis and from planning CTs obtained directly before RT/RCT. We investigated the influence
27 of various factors including several biomarkers on PT-SGR and LN-SGR, which were previously
28 observed to be associated with tumour proliferation⁸⁻¹². We were further interested in the
29 influence of SGR on OS and on the development of new lymph node necrosis and bone or
30 cartilage infiltration.

1 MATERIALS AND METHODS

2 Tumour registry population

3 Patients referred to the Department of Otorhinolaryngology – Head and Neck Surgery, Medical
4 University of Innsbruck, Austria, between 2008 and 2016 with incident histologically confirmed
5 HNSCC were recorded in the clinical tumour registry. Disease was staged according to the
6 seventh edition of the UICC TNM staging system¹³ by an interdisciplinary tumour board.
7 Inclusion criteria comprised histologically proven incident HNSCC at any site of the head and
8 neck region including cancer of unknown primary (CUP), any UICC Stage, RT or RCT as primary
9 treatment and availability of both a diagnostic CT and a planning CT. The review board of the
10 Medical University of Innsbruck had approved the study (UN4590) and informed consent was
11 obtained from all study participants.

12 Diagnostic CT and planning CT

13 At the time of clinical diagnosis, diagnostic CT was performed following the standardized CT
14 head & neck imaging protocols at the Department of Radiology, Medical University of Innsbruck.
15 A GE-Medical Systems Light Speed VCT® or Light speed 16 CT scanner® (GE Medical, Vienna,
16 Austria) was used. The scan area ranged from the frontal sinus to the upper mediastinum with a
17 resolution of 512x512 pixels. Slices were calculated from raw data with 2 millimetres (mm)
18 thickness, collimation of 24x1.2mm and 0.45 pitch. Additional sagittal and coronal images were
19 reconstructed. As contrast medium, Jopamiro 370® (Bracco Austria GmbH, Vienna, Austria) was
20 administered intravenously adjusted to the patient's bodyweight. Planning CT scans were later
21 performed at the Department of Radiation Oncology, Medical University of Innsbruck. Imaging
22 protocols were followed as described above with the same CT scanners, contrast medium,
23 scanning areas, resolutions and calculation protocols. Images from both CT scans were exported
24 in Digital Imaging and Communications in Medicine (DICOM) format using IMPAX EE® (Agfa
25 HealthCare, Bonn, Germany) Picture Archiving and Communication System (PACS®, Cerner,
26 Kansas City USA). LN with a minimal axial diameter >10mm, a central necrosis >3mm or if
27 present in neck levels close to the primary tumour in groups of >3 were classified pathological¹⁴.

1 Volume approximation, specific growth rate and tumour volume doubling time

2 Volumes were calculated as previously described¹⁵. In short, maximum orthogonal diameters in
3 mm were measured for the primary tumour (PT) and the largest pathological cervical lymph (LN)
4 in all three planes in axial and coronal sections (Figure 1). Volumes in millilitres (mL) were
5 approximated employing an ellipsoid formula ($\text{volume} = (\pi * [x * y * z / 1000]) / 6$). The largest cervical
6 LN instead of all pathological cervical lymph nodes was considered sufficient for evaluation
7 based on a high correlation previously observed¹⁵. Central lymph node necrosis and/or cartilage
8 or bone infiltration of the primary tumour was recorded for additional analysis.

9
10 SGRs were assumed to be exponential and defined as the relative volume increase given in
11 percent per day. For calculation of SGR, the equation described by Mehrara and co-authors was
12 applied ($\text{SGR} = \ln[1^{\text{st}} \text{volume} * 2^{\text{nd}} \text{volume}] / [t_2 - t_1]$)⁵. For comparison with earlier studies, doubling
13 times (DT) for primary tumours (PT-DT) and for largest pathological cervical lymph nodes (LN-
14 DT) were calculated as the time difference * LN divided by the logarithm of the volume ratio of
15 the two observations¹⁶.

16 Analysis of EGFR, Ki67 and CD44 expression

17 Tumour biopsies were collected in 4% buffered formalin, fixed overnight and embedded using
18 the ethanol – isopropanol – wax quick 4mm protocol of Histos 5 embedding processor®
19 (Milestone, Bergamo, Italy). Five-micrometre thick paraffin sections were dewaxed and antigen
20 retrieval was performed in a Discovery automated staining system® (Ventana, Tucson, AZ, USA).
21 Primary antibodies were added to the sections by automatic dispensing either as ready-to-use,
22 pre-diluted, stabilized solutions provided by the manufacturers: cyclin dependent kinase
23 inhibitor 2A (p16) INK4® (Ventana, Cat. Nr. 6595294001), Ki67 antigen (Ki67; Linaris E059®,
24 clone MIB-1®, Dossenheim, Germany), CD44 antigen (CD44; Diagnostic Biosystems /Antibodies
25 Online, ABIN1020059, Aachen, Germany) and Epidermal Growth Factor Receptor (EGFR;
26 Invitrogen, Vienna, Austria). Selection of these three biomarkers was based on which were
27 previous observation about their possible associated with tumour proliferation⁸⁻¹²: 1) EGFR is a
28 cell surface receptor which promotes proliferation, invasion, angiogenesis and metastatic
29 spread in HNSCC, if overexpressed⁸. Thus, high expression of EGRF might suggest higher PT-SGR.
30 2) Ki67 is a nuclear protein express on cells in all phases of the cell cycle except in G0-phase.

1 Thus, its expression marks the total fraction of proliferation cells in a tumour⁹⁻¹¹, suggestive of a
2 possible positive correlation with PT-SGR. 3) Positive correlations between CD44 expression and
3 advanced T categories were previously reported in a meta-analysis including thirty studies with
4 2102 patients¹². Since T category is primarily based on maximal tumour diameter, a possible
5 positive correlation between CD44 expression and PT-SGR might be suggested.

6 Immunohistochemical staining was completed by the Discovery automated staining system®
7 (Ventana, Tucson, AZ, USA) using universal secondary antibody solution, haematoxylin
8 counterstaining and the DAB MAP Kit (all Ventana products, Tucson, AZ, USA) as published
9 previously¹⁷. All sections were stained with control mouse and rabbit immunoglobulins, using
10 the same highest concentration as for the primary antibodies, and these controls were not
11 reactive¹⁸. The immunohistochemical reactions were observed independently by two blinded
12 observers, who collected 10 representative tumour cell nests from each specimen¹⁹. These
13 regions were analysed on an Olympus BX50 microscope® (Olympus, Tokyo, Japan) and the
14 staining intensity and representation of tumour cell nests were scored as previously described²⁰.
15 The cut-off for p16-positivity was 70% or more positive tumour cells²¹.

16 **Data analysis**

17 Frequency data were presented in tabular form. For continuous data (volumes and growth
18 rates), means and standard deviations (SD) as well as medians and 25th (p25th) and 75th
19 percentiles (p75th) were provided. The median follow-up time was calculated as described by
20 Schemper and Smith²². Logarithmic transformation was used to analyse volumetric data in
21 regression models. Kruskal-Wallis and Jonckheere-Terpstra tests were used to evaluate the
22 univariate influence of ordinal factors on growth rates. For survival analyses, Kaplan Maier and
23 Cox regression models were used. For Kaplan Meier plots, growth rates were categorized in
24 groups with slow, intermediate and rapid growth rates. All calculations were performed with
25 SPSS 23.0 (IBM Corp., Armonk, NY).

27 **Patient and Public Involvement**

28 The development of the research question was based on previous publications exploring tumor
29 volume in HNSCC¹⁵ and its prognostic value if treated primarily with surgery²³. Neither patients

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 nor the public were involved in the design of the study, the recruitment of the study or the
2 conduct of the study.

For peer review only

1 RESULTS

2 Study population

3 Between 2008 and 2016, 802 patients with incident HNSCC were recorded in the clinical cancer
 4 registry. Of 123 patients treated with primary RT or RCT, PT-volumes and LN-volumes were
 5 calculated from diagnostic and planning-CTs. Tumour sites included oral cavity, oropharyngeal,
 6 hypopharyngeal and laryngeal HNSCC. No patients with tumours of the nasopharynx, the
 7 paranasal sinuses or salivary glands were included. In five patients with CUP-syndrome, no PT-
 8 volume and in 27 patients with N0 stage neck, no LN-volume could be measured. Of the 123
 9 patients, 32 were female. The mean±SD age was 63±10 years ranging from 38 to 87 years.
 10 Median follow up time was 45 months (95% confidence interval 42 to 48 months). Additional
 11 clinical data of the 123 included patients is provided in table 1.

12 **Table 1: Clinical data of included 123 HNSCC patients.**

		No. of patients
Sex	male	89
	female	32
Age	≤ 50 years	11
	51 – 60 years	42
	61 – 70 years	39
	71 – 80 years	26
	≥ 80 years	5
p16	negative	83
	positive	38
Tumour site	oral cavity	16
	oropharynx	55
	hypopharynx	24
	larynx	21
	carcinoma of unknown primary	5
Clinical UICC stage	stage I	4
	stage II	7
	stage III	17
	stage IVa	75
	stage IVb	16
	stage IVc	2

13

1 Time interval, tumour and lymph node volumes

2 Mean±SD time interval between diagnostic CTs and planning CTs was 29±21 days ranging from 6
3 to 146 days. For PT, a total of 119 volume sets from diagnostic CT and planning CT were
4 available (Figure 2). Mean PT-volume from diagnostic CTs was 16.3±20.4mL ranging from 0
5 (CUP-syndrome) to 100.8mL. Mean PT-volume from planning CTs was 24.5±26.8mL ranging
6 from 0 to 160.3mL. The mean PT-volume increase of 6.7±17.2mL during the period between 1st
7 and 2nd CT scans was highly significant (p<0.001).

8 For LN, a total of 96 volume sets were available (Figure 2). Mean LN-volume from diagnostic CTs
9 was 9.2±22.2mL ranging from 0 (N0) to 156.2mL. Mean LN-volume from planning CTs was
10 15.2±31.5mL ranging from 0 to 233.5mL. The mean LN-volume increase of 5.3±17.3mL during
11 the observation period was highly significant (p<0.001). Distributions of these parameters were
12 right skewed. Medians and quartiles for PT-volume and LN-volume are provided in table 2.

13 **Table 2: Volumes of primary tumours and largest pathological cervical lymph nodes in**
14 **diagnostic and planning CTs in 123 patients with HNSCC. Median time interval between 1st**
15 **and 2nd CT scans was 24 days. Specific growth rates were calculated as suggested by Mehrara**
16 **and co-authors⁵, tumour doubling-times were calculated as proposed by Schwartz¹⁶.**

	Diagnostic CT volume ¹⁾ [ml]	Planning CT volume ¹⁾ [ml]	SGR ²⁾ [%/day]	DT ³⁾
Primary tumour	9.4 (3.3; 21.4)	16.7 (5.4; 31.6)	1.4 (0.6; 2.7)	43 (24; 85)
Lymph node	2.0 (0.2; 9.5;)	3.7 (0.6; 19.4)	1.2 (0.3; 2.5)	41 (25; 80)

17 1) Median (25th and 75th percentile)

18 2) Specific growth rate (median, 25th and 75th percentile) percent per day

19 3) Tumour doubling time in days (median, 25th and 75th percentile)

20 Specific growth rates (SGR) and tumour doubling times (DT)

21 Mean±SD PT-SGR was 1.8%±1.8%/day ranging from minus 2.6%/day (volume decrease) to
22 8.6%/day. Mean LN-SGR was 1.7%±2.0%/day ranging from minus 1.5% to 11.0%/day. PT-SGR
23 and LN-SGR were right-skewed. For medians and quartiles see table 2. Mean PT-SGR of tumours
24

1 of the oral cavity, oropharynx, hypopharynx and larynx were $3.1\pm 1.5\%/day$, $1.8\pm 1.7\%/day$,
 2 $2.0\pm 2.0\%/day$ and $1.5\pm 2.1\%/day$, respectively. Mean LN-SGR for the primary tumour sites
 3 oral cavity, oropharynx, hypopharynx and larynx were $3.4\pm 3.9\%/day$, $1.9\pm 2.2\%/day$,
 4 $1.9\pm 1.4\%/day$ and $0.8\pm 1.1\%/day$, respectively. For tumour sites, medians and quartiles are
 5 provided in table 3.

6 **Table 3: Specific growth rates (SGR) for primary tumours (PT) and largest pathological cervical**
 7 **lymph nodes (LN) for common tumour sites of 123 patients with incident HNSCC.**

Tumour site	n	PT-SGR ¹⁾	LN-SGR ¹⁾
Oral cavity	15	2.4 (1.0; 3.9)	0.8 (0.0; 1.5)
Oropharynx	55	1.4 (0.7; 2.6)	2.5 (0.4; 2.6)
Hypopharynx	25	1.7 (0.6; 2.7)	2.1 (0.6; 2.9)
Larynx	21	1.0 (0.3; 3.1)	0.8 (0.0; 1.4)
Carcinoma of unknown primary	5	0.0 (0.0; 0.0)	1.4 (1.1; 5.2)

8 1) Median (25th and 75th percentile)

9
 10 Median PT-DT was 43 days. The 25th percentile was 24 and the 75th percentile 85 days. Median
 11 LN-DT was 41 days. The 25th percentile was 25 and the 75th percentile 80 days (Tab. 2). PT-DT
 12 and LN-DT were considerably right skewed.

13 Factors influencing specific growth rates

14 PT-SGR was independent of the initial PT-volume in diagnostic CT ($p=0.19$). PT-SGR did also not
 15 depend on the interval between 1st and 2nd CT ($p=0.14$). Moreover, tumour site had no
 16 significant impact on SGR ($p=0.58$; Tab. 3). Interestingly, PT-SGR positively correlated with the
 17 expression of EGFR, Ki67 and CD44 ($p=0.02$; $p=0.02$ and $p=0.03$, respectively; Figure 3). The
 18 expression of p16 had no influence on PT-SGR ($p=0.21$).

19
 20 In contrast, LN-SGR depended on the initial LN-volume measured in diagnostic CT ($p=0.003$)
 21 with higher LN-SGRs in lymph nodes with larger LN-volumes in the 1st CT. Also, the interval
 22 between the diagnostic CT and planning CT significantly influenced LN-SGR ($p=0.003$). The
 23 longer the interval, the lower the observed LN-SGR. Moreover, LN-SGR was significantly

1 influenced by tumour site ($p=0.032$; Tab. 3) with smallest growth rates in lymph nodes from
2 laryngeal HNSCC ($p=0.003$). In contrast to PT-SGR, neither EGFR, Ki67, CD44 nor p16 expression
3 in PTs significantly correlated with LN-SGR ($p=0.12$; $p=0.31$; $p=0.75$ and $p=0.81$, respectively).
4

5 **Specific-growth-rate and overall survival**

6 PT-SGR nearly missed significant impact on OS when used as a single covariate in a Cox
7 regression model (log rank $p=0.054$). For Kaplan Meier analyses, PT-SGR were categorized in 3
8 groups: slow ($< 0.3\%/day$; $n=22$); intermediate ($0.3\% \leq 3\%/day$; $n=73$) and rapid ($>3\%/day$;
9 $n=26$). Survival curves of these 3 SGR groups did not differ significantly (log rank $p=0.45$; Figure
10 4). Likewise, LN-SGR had no significant impact on OS as a covariate in Cox regression (log rank
11 $p=0.83$) nor in Kaplan Meier analyses (log rank $p=0.97$; data not shown).
12

12 **Cartilage or bone infiltration and central lymph node necrosis**

13 Cartilage or bone infiltration was observed in diagnostic CTs of 40/123 (33%) patients and in
14 planning CTs of 50/123 (41%) patients. Thus, during the median 24 days interval between the
15 two CTs, new cartilage or bone infiltration occurred in 10 patients, which was not influenced by
16 PT-SGR ($p=0.918$). However, cartilage or bone infiltration had a significant negative impact on
17 survival ($p=0.003$) and was significantly more frequent in p16 negative tumours ($p=0.02$).
18

19 Lymph node necrosis was observed in diagnostic CTs of 74/97 (76%) patients. LN-SGR was
20 significantly higher in patient with lymph node necrosis ($p<0.001$), was associated with poorer
21 survival ($p=0.03$) and did not depend on p16 status. Lymph node necrosis was observed in
22 planning CTs of 82/97 (85%) patients. Thus, during the median 24 days interval between the two
23 CTs, new lymph node necrosis occurred in 8 patients, which was not influenced by LN-SGR
24 ($p=0.818$). Central lymph node necrosis had a significant negative impact on survival ($p<0.05$).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 DISCUSSION

2 Long waiting times for treatment of head and neck cancer result in decreased overall survival¹⁻³.

3 One reason might be meantime tumour growth. We examined tumour growth during the time
4 between the initial diagnostic CT scan and the planning CT for RT or RCT in 123 patients with
5 incident HNSCC. The majority of the patients suffered from incident stage Iva oropharyngeal
6 HNSCC.

7
8 The mean interval between 1st and 2nd CT was 29 days ranging from 6 to 146 days. In this time,
9 diagnostic work up, interdisciplinary tumour board presentation and pre-treatment procedures
10 including dental treatments and application of percutaneous gastrostomies were carried out.
11 PT- and LN-volumes in diagnostic and planning CTs were assessed using identical protocols. PT-
12 SGR and LN-SGR were calculated as proposed by Mehrara and co-authors⁵. This mean interval is
13 comparable to previously reports¹. Moreover, it is considerably shorter than intervals of 46 to
14 52 days, which were reported as threshold for decreased OS². From a clinical perspective, this is
15 considered positive. However, in terms of exploring SGR's in advanced stage HNSCC, this
16 interval may not be sufficient to accurately determine great changes in PT-volume or LN-
17 volume.

18
19 Due to the skewness of volumetric data, the median was considered an appropriate measure of
20 central tendency, but the mean is also provided for comparison with previous publications.
21 Mean PT-volume in diagnostic CTs was approximately 16mL (median≈9mL). In planning CTs of
22 the same patients 3-4 weeks later, mean PT-volume was approximately 25mL (median≈17mL;
23 Tab. 2). These PT-volumes are in line with previous publications reporting mean volumes of 11-
24 37mL²³⁻²⁶. Mean LN-volume measured in diagnostic CTs was 9mL (median≈2mL) and
25 approximately 15mL (median≈4mL) in planning CTs (Tab 2). Previously reported mean LN-
26 volumes were considerably larger with 22-25mL^{27, 28}. However, in these studies the volume of all
27 pathological cervical lymph nodes was measured instead of only the largest one as in this study.

28
29 Tumour and pathological lymph node growth can be reported as doubling time (DT) or specific
30 growth rates (SGR). DT is the number of days the tumour needs to double its volume⁴. The

1
2
3 1 lower the DT, the faster the tumour growth. Since DT was frequently reported in earlier studies,
4
5 2 it was provided for comparison. SGR is defined as relative increase of volume in percent per day.
6
7 3 The resulting variable is constant, linear and independent of the initially measured volumes⁵.
8
9 4 SGR is considered less affected by measurement uncertainties of short time intervals and minor
10
11 5 volume differences than DT⁵.
12
13 6

14 7 For both, DT and SGR, tumour volumes are required. A volume approximation method from CT
15
16 8 scans, which reflects frequently available diagnostics, was used here. This approximation was
17
18 9 based on measurements of maximum orthogonal diameters, similar to a formula described in
19
20 10 1990 by MacDonald and co-workers to approximate volumes of brain tumours²⁹. The method
21
22 11 employed an ellipsoid formula, which was applicable over a wide range of PT and LN sizes and
23
24 12 resulted only in a slight underestimation of 8% of the PT-volume measured with the reference
25
26 13 method¹⁵. A similar approximation method has also been used by Jensen and co-authors³⁰.
27
28 14 More sophisticated segmentation- and more modern imaging techniques, may have allowed for
29
30 15 better tumour margin delineation. However, the first require specific workstations with limited
31
32 16 availability¹⁵ (i.e. semi-automated or automated slice-by-slice segmentation) and large inter-
33
34 17 observer variations may remain³¹. The latter may allow better visualisation of oropharyngeal
35
36 18 and oral HNSCC (i.e. magnetic resonance imaging MRI) or better visualisation of locally
37
38 19 advanced tumours (i.e. fluorodesoxyglucose positron emission tomography FDG-PET). However,
39
40 20 both imaging techniques are not as frequently available as CT scans and other limitations apply.
41
42 21 For MRIs blurred tumour margins may be observed if patients swallow or breathe, for FDG-PET
43
44 22 a lack of spatial resolution may be disadvantageous in smaller HNSCC tumours³¹.
45
46 23

47 24 Mean primary tumour specific growth rates (PT-SGR) in incident HNSCC was 1.8%/day (Tab. 2),
48
49 25 unimodally distributed, slightly right skewed and independent of the initial PT-volume, which
50
51 26 supports the basic concept underlying SGR calculation. The interval between diagnostic CT and
52
53 27 planning CT did not influence PT-SGR ($p=0.1$), suggesting that no marked growth deceleration
54
55 28 occurred with longer waiting times. Interestingly, PT-SGRs did not significantly differ by tumour
56
57 29 site ($p=0.6$; Tab 3). Murphy and colleagues observed a lower median SGR of 0.74%/day in
58
59 30 patients with oropharyngeal cancer⁶. However, the authors did not include sites with faster

1 tumour growth such as the oral cavity (median SGR 2.4%/day) and hypopharynx (median SGR
2 2.0%/day). Moreover, most of the patients reported by Murphy and colleagues had T1 or T2
3 HNSCC and were p16 positive.

4
5 The median PT-DT in this study was 43 days. The 25th percentile was 24 and the 75th percentile
6 85 days. Median LN-DT was 41 days. The 25th percentile was 25 and the 75th percentile 80 days
7 (Tab. 2). Jensen and co-authors reported a slower growth rate in 61 patients with HNSCC with a
8 median PT-DT of 99 days. The authors however additionally stated that half of the patients
9 showed a faster growth rate with a PT-DT of 30 days³⁰. When compared with DT of other solid
10 tumours, this means that HNSCC reveal rapid tumour growth. For breast cancer, Ingebly and co-
11 authors reported a median DT of 285 days⁴. For lung cancer, DTs vary depending on histology
12 between median 42 days for metastases as reported by Loeffler and colleagues and 181 for non-
13 small-cellular lung cancer as reported by Winer-Muram and co-workers^{4,32}. For pancreatic
14 adenocarcinoma, Furkawa and colleagues reported a mean PT-DT of 144 days³². For Sarcomas
15 median PT-DTs of 35 days were reported by Blomqvist and co-authors³². Additional median PT-
16 DTs for additional solid tumours are provided in table 4.

17
18 **Table 4: Reported tumour volume doubling times for selected solid tumours*.**

Tumour	Median DT [days]	n
Present study	47	123
HNSCC ³⁰	99**	61
Breast cancer ⁴	285	16
Lung bronchioalveolarcarcinoma ³²	181	9
Non small-cell lung carcinoma ³²	181	6
Lung metastasis ⁴	42	24
Pancreatic adenocarcinoma ³²	144	9
Sarcoma ³²	35	21

1
2
3 1 *modified after Mehrara and co-authors³²

4
5 2 **Jensen and co-workers also stated tumour volume doubling times for the faster growing half
6
7 3 of the patients with a median PT-DT of 30³⁰.

8
9 4
10 5 PT-SGRs significantly correlated with the expression of EGFR, Ki67 and CD44 (p=0.021; p=0.018
11 6 and p=0.031, respectively) with higher PT-SGRs in patients with higher expression of the three
12 7 biomarkers (Figure 3). These correlations appear biologically sound. A correlation of clinical
13 8 tumour growth rates and expression of these biomarkers within the tumour of the same
14 9 patients was not yet reported. EGFR is a cell surface receptor which promotes proliferation,
15 10 invasion, angiogenesis and metastatic spread in HNSCC, if overexpressed⁸. Ki-67 is a nuclear
16 11 protein expressed on cells in all phases of the cell cycle except in G0-phase. Thus, its expression
17 12 marks the total fraction of proliferating cells in a tumour⁹. In laryngeal and hypopharyngeal SCC,
18 13 an association between Ki67 expression and advanced tumour stages has been reported¹⁰⁻¹¹. In
19 14 line with our observation of a correlation of CD44 expression and PT-SGR, an association
20 15 between advanced T categories and high CD44 expressions has been reported in a meta-
21 16 analysis including thirty studies with 2102 patients¹². No significant correlation between PT-SGR
22 17 and p16 expression was observed (p=0.81). This observation differs from previous observations
23 18 made by Murphy and colleagues. The authors observed that p16 expression correlated well with
24 19 PT-SGR with faster growth rates in p16 negative HNSCCs. However, the authors included
25 20 oropharyngeal HNSCC only and the majority (79%) were p16 positive tumours⁶. When used as a
26 21 covariate in a Cox model, PT-SGR had no significant effect on OS (log rank p=0.054). No
27 22 significant differences of survival curves were also observed, if PT-SGR were categorized in
28 23 groups of low, medium and high growth rates (log rank p=0.45; Figure 4). In contrast, van Bockel
29 24 and co-worker observed a significant association between PT-SGR and OS in laryngeal cancer⁷.

30 25
31 26 To our knowledge, no data on lymph node specific growth rates (LN-SGR) in HNSCC have been
32 27 previously reported. In the investigated patients, the mean LN-SGR was 1.7%/day, similar to
33 28 mean PT-SGR (Tab. 2). In contrast to PT-SGR, LN-SGR did depend on initial LN-volumes in
34 29 diagnostic CT scans (p=0.003) with higher LN-SGRs in lymph nodes with larger initial LN-
35 30 volumes. Also, the interval between diagnostic CT and planning CT significantly influenced LN-

1 SGR ($p=0.003$). The longer the interval, the lower the observed LN-SGR, suggesting growth
2 slowdown. Moreover, LN-SGR was significantly influenced by tumour site ($p=0.03$; Tab. 3), with
3 smallest growth rates in lymph nodes from laryngeal HNSCC. In contrast to PT-SGR, LN-SGR did
4 not depend on expressions of EGFR, Ki67, CD44 nor p16 expression in primary tumours
5 ($p=0.115$; $p=0.311$; $p=0.746$ and $p=0.809$ respectively). In LN, specific growth rates had no
6 significant impact on OS either ($p>0.05$).

7
8 New cartilage or bone infiltrations during the observation period were observed in 10 patients
9 and new central lymph node necroses were observed 8 patients. Specific growth rates had no
10 significant impact on the development of either of them. Both, initial cartilage or bone
11 infiltration and central lymph node necrosis were associated with worse survival. However,
12 probably due to the low number of events, no significant impact of new cartilage or bone
13 infiltration nor new central lymph node necrosis on survival was observed in Kaplan Meier
14 analysis (both log rank $p>0.05$).

15
16 Certain limitation of the present study need to be addressed. Firstly, this small numbered
17 retrospective study predominantly exploring patients with advanced stage oropharyngeal
18 HNSCC should be supplemented by larger, prospective investigation, which also included
19 patients with limited disease of all common HNSCC tumour sites. Secondly, the approximation
20 method¹⁵ proposed here may be easily performed from frequently available CT scans over a
21 wide range of different PT- and LN-volumes. However, more sophisticated segmentation- and
22 more modern imaging techniques may have allowed for better tumour margin delineation and
23 hence form more accurate SGRs. Thirdly, the comparably short interval between diagnostic CT
24 scans and planning CT scans may be considered positive from a clinical perspective. However, in
25 terms of exploring SGRs in advanced stage HNSCC, this interval may not be sufficient to
26 accurately determine great changes in PT- and LN-volume.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **CONCLUSION**

2 Head and neck squamous cell carcinomas are rapidly growing malignancies. Primary tumours
3 and lymph nodes grow more than 1% per day. Consequently, time matters, and treatment must
4 not be delayed.

For peer review only

1 ABBREVIATIONS

2	CD44	CD44 antigen
3	CT	computed tomography
4	DICOM	Digital Imaging and Communications in Medicine
5	DT	tumour volume doubling time
6	EGFR	epidermal growth factor receptor
7	FDG-PET	fluorodesoxyglucose positron emission tomography
8	HNSCC	head and neck squamous cell carcinoma
9	Ki67	Ki67 antigen
10	LN	largest pathological cervical lymph node
11	LN-DT	largest pathological cervical lymph node doubling time
12	LN-SGR	largest pathological cervical lymph node specific growth rate
13	MRI	magnetic resonance imaging
14	p16	Cyclin-dependent kinase inhibitor 2A
15	PACS	Picture Archiving and Communication System
16	PT	primary tumour
17	PT-DT	primary tumour volume doubling time
18	PT-SGR	primary tumour specific growth rate
19	RCT	radiochemotherapy
20	RT	radiotherapy
21	SD	standard deviation
22	SGR	specific growth rate
23	TNM	tumour, node, metastasis
24	UICC	Union internationale contre le cancer

1 **REQUIRED STATEMENTS**

2 **Acknowledgements**

3 This work has not yet been previously presented at a conference or as a conference abstract.

4 **Copyright statement**

5 The Corresponding Author has the right to grant on behalf of all authors and does grant on
6 behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd
7 to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL
8 products and sublicenses such use and exploit all subsidiary rights, as set out in our licence.

10 **Ethics statement**

11 The review board of the Medical University of Innsbruck had approved the study (UN4590) and
12 informed consent was obtained from all study participants. All procedures performed in studies
13 involving human participants were in accordance with the ethical standards of the institutional
14 review board and with the 1964 Helsinki declaration and its later amendments or comparable
15 ethical standards.

16 **Competing interest and funding statement**

17 All authors have completed the Unified Competing Interest form and declare: no support from
18 any organisation for the submitted work; no financial relationships with any organisations that
19 might have an interest in the submitted work in the previous three years, no other relationships
20 or activities that could appear to have influenced the submitted work.

21 **Contributorship statement**

22 Daniel Dejaco has written major parts of the manuscript and performed the calculations of
23 tumour and lymph node volumes. Teresa Steinbichler was involved in establishing the study
24 concept, design and the internal review process of the manuscript. Schartinger Volker
25 established the population based tumour registry from which patients were enrolled. He further
26 obtained the ethics committee approval for the study. Natalie Fischer performed additional
27 tumor and pathological cervical lymph node measurements and was involved in the internal

1 review process of the manuscript. Maria Anegg has performed additional calculations and data
2 base work in the population based tumour registry. Jozef Dudas performed the
3 immunohistochemical staining of the tumour biopsies and was involved in establishing the
4 study concept, design and the internal review process of the manuscript. Andrea Posch
5 provided the radiotherapy-planning CT scans and performed performed additional tumor and
6 pathological cervical lymph node measurements. Gerlig Widmann supervised the tumor and
7 pathological cervical lymph node measurements as an experienced head and neck radiologist.
8 Herbert Riechelmann supervised the writing process of the manuscript and performed all
9 statistical calculations in the manuscript.

10 **Transparency declaration**

11 The Corresponding Author affirms that the manuscript is an honest, accurate, and transparent
12 account of the study being reported; that no important aspects of the study have been omitted;
13 and that any discrepancies from the study have been explained.

14 **Details of ethical approval and patient consent**

15 The review board of the Medical University of Innsbruck had approved the study (UN4590) and
16 informed consent was obtained from all study participants.

17 **Data sharing**

18 No additional data from the study is available.

1 REFERENCES

- 2 1. Murphy CT, Galloway TJ, Handorf EA, et al. Increasing time to treatment initiation for head
3 and neck cancer: an analysis of the National Cancer Database. *Cancer* 2015;121(8):1204-13. doi:
4 10.1002/cncr.29191 [published Online First: 2014/12/11]
- 5 2. Murphy CT, Galloway TJ, Handorf EA, et al. Survival Impact of Increasing Time to Treatment
6 Initiation for Patients With Head and Neck Cancer in the United States. *J Clin Oncol*
7 2016;34(2):169-78. doi: 10.1200/jco.2015.61.5906 [published Online First: 2015/12/03]
- 8 3. Stefanuto P, Doucet JC, Robertson C. Delays in treatment of oral cancer: a review of the
9 current literature. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2014;117(4):424-9. doi:
10 10.1016/j.oooo.2013.12.407 [published Online First: 2014/02/22]
- 11 4. Steel GG, Lamerton LF. The growth rate of human tumours. *Br J Cancer* 1966;20(1):74-86.
12 [published Online First: 1966/03/01]
- 13 5. Mehrara E, Forssell-Aronsson E, Ahlman H, et al. Specific growth rate versus doubling time for
14 quantitative characterization of tumor growth rate. *Cancer Res* 2007;67(8):3970-5. doi:
15 10.1158/0008-5472.can-06-3822 [published Online First: 2007/04/19]
- 16 6. Murphy CT, Devarajan K, Wang LS, et al. Pre-treatment tumor-specific growth rate as a
17 temporal biomarker that predicts treatment failure and improves risk stratification for
18 oropharyngeal cancer. *Oral Oncol* 2015;51(11):1034-40. doi:
19 10.1016/j.oraloncology.2015.09.001 [published Online First: 2015/09/28]
- 20 7. van Bockel LW, Verduijn GM, Monninkhof EM, et al. The importance of actual tumor growth
21 rate on disease free survival and overall survival in laryngeal squamous cell carcinoma.
22 *Radiother Oncol* 2014;112(1):119-24. doi: 10.1016/j.radonc.2014.06.004 [published Online First:
23 2014/07/06]
- 24 8. Bossi P, Resteghini C, Paielli N, et al. Prognostic and predictive value of EGFR in head and neck
25 squamous cell carcinoma. *Oncotarget* 2016;7(45):74362-79. doi: 10.18632/oncotarget.11413
26 [published Online First: 2016/08/25]
- 27 9. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol*
28 2000;182(3):311-22. doi: 10.1002/(sici)1097-4652(200003)182:3<311::Aid-jcp1>3.0.Co;2-9
29 [published Online First: 2000/02/01]

- 1
2
3 1 10. Ashraf MJ, Maghbul M, Azarpira N, et al. Expression of Ki67 and P53 in primary squamous
4 cell carcinoma of the larynx. *Indian J Pathol Microbiol* 2010;53(4):661-5. doi: 10.4103/0377-
5 2 4929.72019 [published Online First: 2010/11/04]
6 3
7 4 11. Wang JX, Zhang YY, Yu XM, et al. Role of centromere protein H and Ki67 in relapse-free
8 survival of patients after primary surgery for hypopharyngeal cancer. *Asian Pac J Cancer Prev*
9 5 2012;13(3):821-5. [published Online First: 2012/05/29]
10 6
11 7 12. Chen J, Zhou J, Lu J, et al. Significance of CD44 expression in head and neck cancer: a
12 systemic review and meta-analysis. *BMC Cancer* 2014;14:15. doi: 10.1186/1471-2407-14-15
13 8
14 9 [published Online First: 2014/01/15]
15 10
16 11 13. Sobin L WC. *TNM Classification of Malignant Tumours*: Wiley-Blackwell 2009.
17 12
18 13 14. van den Brekel MW, Stel HV, Castelijns JA, et al. Cervical lymph node metastasis: assessment
19 of radiologic criteria. *Radiology* 1990;177(2):379-84. doi: 10.1148/radiology.177.2.2217772
20 11
21 12 [published Online First: 1990/11/01]
22 13
23 14 15. Dejaco D, Url C, Schartinger VH, et al. Approximation of head and neck cancer volumes in
24 contrast enhanced CT. *Cancer Imaging* 2015;15:16. doi: 10.1186/s40644-015-0051-3 [published
25 16
26 Online First: 2015/10/01]
27 17
28 18 16. Schwartz M. A biomathematical approach to clinical tumor growth. *Cancer* 1961;14:1272-94.
29 15
30 [published Online First: 1961/11/01]
31 16
32 17 17. Dudas J, Schartinger VH, Romani A, et al. Cell cycle association and hypoxia regulation of
33 excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck
34 18
35 cancer. *Tumour Biol* 2014;35(8):7807-19. doi: 10.1007/s13277-014-2001-2 [published Online
36 19
37 First: 2014/05/13]
38 20
39 21 18. Schartinger VH, Falkeis C, Laimer K, et al. Neuroendocrine differentiation in head and neck
40 21
41 squamous cell carcinoma. *J Laryngol Otol* 2012;126(12):1261-70. doi:
42 22
43 10.1017/S0022215112002265
44 23
45 24 19. Rietbergen MM, Snijders PJ, Beekzada D, et al. Molecular characterization of p16-
46 24
47 immunopositive but HPV DNA-negative oropharyngeal carcinomas. *Int J Cancer*
48 25
49 26 2014;134(10):2366-72. doi: 10.1002/ijc.28580 [published Online First: 2013/11/20]
50 27
51 28
52
53
54
55
56
57
58
59
60

- 1
2
3 1 20. Smilek P, Dusek L, Vesely K, et al. Correlation of expression of Ki-67, EGFR, c-erbB-2, MMP-9,
4 p53, bcl-2, CD34 and cell cycle analysis with survival in head and neck squamous cell cancer. J
5 Exp Clin Cancer Res 2006;25(4):549-55. [published Online First: 2007/02/22]
6
7 21. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR
8 expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007;120(8):1731-8. doi:
9 10.1002/ijc.22355 [published Online First: 2007/01/20]
10
11 22. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control
12 Clin Trials 1996;17(4):343-6. [published Online First: 1996/08/01]
13
14 23. Dejaco D, Steinbichler T, Schartinger VH, et al. Prognostic value of tumor volume in patients
15 with head and neck squamous cell carcinoma treated with primary surgery. Head Neck
16 2018;40(4):728-39. doi: 10.1002/hed.25040 [published Online First: 2017/12/23]
17
18 24. Davis KS, Lim CM, Clump DA, et al. Tumor volume as a predictor of survival in human
19 papillomavirus-positive oropharyngeal cancer. Head Neck 2016;38 Suppl 1:E1613-7. doi:
20 10.1002/hed.24287 [published Online First: 2015/12/19]
21
22 25. Kneijens JL, Hauptmann M, Pameijer FA, et al. Tumor volume as prognostic factor in
23 chemoradiation for advanced head and neck cancer. Head Neck 2011;33(3):375-82. doi:
24 10.1002/hed.21459 [published Online First: 2010/07/16]
25
26 26. Oemus D, Inhestern J, Schmalenberg H, et al. Prognostic value of tumor volumetry data of
27 routine imaging data in a head and neck cancer registry. Eur Arch Otorhinolaryngol
28 2014;271(9):2531-7. doi: 10.1007/s00405-013-2800-x [published Online First: 2013/11/07]
29
30 27. Chen SW, Yang SN, Liang JA, et al. Prognostic impact of tumor volume in patients with stage
31 III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent
32 chemoradiotherapy. Head Neck 2009;31(6):709-16. doi: 10.1002/hed.21011 [published Online
33 First: 2009/03/05]
34
35 28. Doweck I, Denys D, Robbins KT. Tumor volume predicts outcome for advanced head and
36 neck cancer treated with targeted chemoradiotherapy. Laryngoscope 2002;112(10):1742-9. doi:
37 10.1097/00005537-200210000-00006 [published Online First: 2002/10/09]
38
39 29. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG. Response criteria
40 for phase II studies of supratentorial malignant glioma. J Clin Oncol.1990;8:1277-80. doi:
41 10.1200/JCO.1990.8.7.1277.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 30. Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy
4 2 in head and neck cancer. *Radiother Oncol* 2007;84(1):5-10.
- 5 3 31. Grégoire V, Evans M, Le QT, et al. Delineation of the primary tumour Clinical Target Volumes
6 4 (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma:
7 5 AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC
8 6 CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus
9 7 guidelines. *Radiother Oncol*. 2018 Jan;126(1):3-24. doi: 10.1016/j.radonc.2017.10.016 [published
10 8 Online First: 2017/11/24]
- 11 9 32. Mehrara E, Forssell-Aronsson E, Ahlman H, et al. Quantitative analysis of tumor growth rate
12 10 and changes in tumor marker level: specific growth rate versus doubling time. *Acta Oncol*
13 11 2009;48(4):591-7. doi: 10.1080/02841860802616736 [published Online First: 2009/03/31]
- 14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **1 FIGURE LEGENDS**

5
6
7 **2 Figure 1: Tumour growth assessment using maximal orthogonal tumour diameters from axial**
8 **3 contrast enhanced diagnostic CT scans (A) and subsequent planning CT scans (B)**

9 Axial contrast enhanced diagnostic CT scan (A) and subsequent planning CT scan (B) 46 days
10 later of a cT4a cN2b cM0 squamous cell carcinoma of the oral cavity. The maximum anterior-
11 posterior and medio-lateral tumour diameters (white lines) were measured from axial scans, the
12 cranio-caudal tumour diameters were measured from corresponding coronal scans (not
13 depicted). The tumour volume was assessed as previously described using an ellipsoid
14 formula¹⁵. PT-volume from diagnostic CT was 14.8mL, PT-volume from planning CT was 51.0mL
15 translating to a PT-SGR of 2.8%/day.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 Figure 2: Correlation of primary tumour volume (A) and largest pathological lymph node**
4 **2 volume (B) measured from diagnostic CT scans and a planning CT scans**

5
6
7 3 Scattergram of primary tumour volumes (A) and largest pathological lymph node volume (B)
8
9 4 measured from diagnostic CT scans (x-axis) planning CT scans (y-axis). Both axes are on log scale.
10
11 5 The diagonal line represents the line of identity. Dots above this line indicate volume increases.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Figure 3: Specific growth rates of the primary tumours and percentage of Ki67 positive cells**
2 Percentage of Ki67 positive immunohistochemistry in tumour samples of HNSCC patients and
3 according primary tumour specific growth rates. The percentage of Ki67 positive cells was
4 grouped in 0%, 1 to 30%, 31 to 60% and more than 60% of cancer cells (x-axis). Mean specific
5 growth rates of HNSCC primary tumour (y-axis) were obtained 119 patients. Small bars
6 represent standard deviation. PT-SGR positively correlated with the expression of Ki67
7 (Jonckheere-Terpstra $p=0.02$).
8

1
2
3 **1 Figure 4: Kaplan Maier plot for specific growth rates of primary tumours grouped by low,**
4 **2 medium and high growth rate**

5
6
7 3 Kaplan Maier plot of specific growth rates (SGR) of primary tumours grouped by low (black line;
8 4 $SGR < 0.3\%/day$; $n=22$); medium (dark grey line; $0.3\% \leq SGR < 3\%/day$; $n=73$) and high (pale grey
9 5 line; $SGR > 3\%/day$; $n=26$) growth rates. X-axis represents time in months, Y-axis overall survival.
10
11
12 6 The survival curves of the 3 specific growth rate groups did not differ significantly (log rank
13
14 7 $p=0.45$).
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Tumour growth assessment using maximal orthogonal tumour diameters from axial contrast enhanced diagnostic CT scans (A) and subsequent planning CT scans (B) Axial contrast enhanced diagnostic CT scan (A) and subsequent planning CT scan (B) 46 days later of a cT4a cN2b cM0 squamous cell carcinoma of the oral cavity. The maximum anterior-posterior and medio-lateral tumour diameters (white lines) were measured from axial scans, the cranio-caudal tumour diameters were measured from corresponding coronal scans (not depicted). The tumour volume was assessed as previously described using an ellipsoid formula⁹. PT-volume from diagnostic CT was 14.8mL, PT-volume from planning CT was 51.0mL translating to a PT-SGR of 2.8%/day.

11x7mm (600 x 600 DPI)




Figure 2: Correlation of primary tumour volume (A) and largest pathological lymph node volume (B) measured from diagnostic CT scans and a planning CT scans
Scattergram of primary tumour volumes (A) and largest pathological lymph node volume (B) measured from diagnostic CT scans (x-axis) planning CT scans (y-axis). Both axes are on log scale. The diagonal line represents the line of identity. Dots above this line indicate volume increases.

16x7mm (600 x 600 DPI)




Figure 3: Specific growth rates of the primary tumours and percentage of Ki67 positive cells
Percentage of Ki67 positive immunohistochemistry in tumour samples of HNSCC patients and according primary tumour specific growth rates. The percentage of Ki67 positive cells was grouped in 0%, 1 to 30%, 31 to 60% and more than 60% of cancer cells (x-axis). Mean specific growth rates of HNSCC primary tumour (y-axis) were obtained 119 patients. Small bars represent standard deviation. PT-SGR positively correlated with the expression of Ki67 (Jonckheere-Terpstra $p=0.02$).

16x14mm (600 x 600 DPI)




Figure 4: Kaplan Maier plot for specific growth rates of primary tumours grouped by low, medium and high growth rate

Kaplan Maier plot of specific growth rates (SGR) of primary tumours grouped by low (black line; $\text{SGR} < 0.3\%/ \text{day}$; $n=22$); medium (dark grey line; $0.3\% \leq \text{SGR} < 3\%/ \text{day}$; $n=73$) and high (pale grey line; $\text{SGR} > 3\%/ \text{day}$; $n=26$) growth rates. X-axis represents time in months, Y-axis overall survival. The survival curves of the 3 specific growth rate groups did not differ significantly (log rank $p=0.45$).

16x14mm (600 x 600 DPI)

STROBE Statement: “Time matters – the fast growth of head and neck squamous cell carcinoma”

	Item No	Answer
Title and abstract	1	(a) The retrospective study design was described in the “Abstract” section, page 2, line 7, the “Strengths and Limitations of the Study” section, page 3 and the “Introduction” section, page 5. (b) An informative and balanced summary of what was done was provided in the “Abstract” section, page 2.
Introduction		
Background/rationale	2	The scientific background and rationale for the investigation was reported in the “Introduction” section of the manuscript, page 5.
Objectives	3	The objective of the study was specified in the “Abstract” section, page 2 and at the end of the “Introduction” section, page 2.
Methods		
Study design	4	Key elements of the study design were mentioned early in the “Abstract” section, page 2 and the “Introduction” section, page 5 of the manuscript. Additional details of the study design were outlined in the “Methods”, page 6 to 8.
Setting	5	The setting, location, relevant dates, including period of recruitment and data collection was included in the “Methods” section, page 6 and in the “Results” section, page 9.
Participants	6	(a) <i>Cohort study</i> — The eligibility criteria and the sources and methods of selection of participants are provided in detail in the “Methods” section, page 6. (b) <i>Cohort study</i> — No matching was performed in this study.
Variables	7	All outcomes, predictors, potential confounders and effect modifiers were defined, presented and discussed in the “Methods” section, page 6 to 8, “Results” section, page 9 to 12 and “Discussion” section, page 13 to 16. Diagnostic criteria were provided in the “Methods” section, page 6, when applicable.
Data sources/ measurement	8*	Source of data and details of methods was provided in the “Methods” section, page 6 and 8.
Bias	9	Potential sources of bias were addressed in the “Discussion” section, page 13 to 16.
Study size	10	An explanation how the study size was arrived at was provided in the “Method” section, page 6.
Quantitative variables	11	An explanation how quantitative variables were handled in the analyses was provided in the “Methods” section, page 8.
Statistical methods	12	(a) All statistical methods were described in the “Methods” section, page 8. (b) All methods for subgroup analyses of the presented study were described in the “Methods” section, page 8. (c) An explanation how missing data was addressed was provided in the “Methods” section, page 8, “Results” section, pages 9 to 12 and “Discussion” section, pages 13 to 16. (d) <i>Cohort study</i> —No loss to follow-up occurred due to the study design. (e) No sensitivity analyses were performed in the study.

Continued on next page

Results		
Participants	13*	(a) Numbers of individuals at each stage of the study was reported in the “Results” section, page 9 and the “Discussion” section, page 13. (b) No non-participation occurred due to the study design. (c) No flow diagram was used for this study.
Descriptive data	14*	(a) Clinical characteristics of study participants were provided in table 1, page 9. (b) Number of participants with missing data for each variable of interest was provided in the “Results” section, page 9 and in table 1, page 9. (c) <i>Cohort study</i> —Follow-up time was summarised as time between diagnostic computed tomography scan and planning computed tomography scan in this study provided in the “Results” section, page 9.
Outcome data	15*	<i>Cohort study</i> — Numbers of outcome events was provided in the “Results” section, page 9 to 12.
Main results	16	(a) Means, medians, standard deviations, 95% confidence intervals and 25 th and 75 th percentiles were provided in the “Results” section, page 9 to 12, if applicable. (b) Category boundaries for continuous variables were specified in the “Methods” section, page 8 and “Results” section, pages 9 to 12. (c) No relative risk estimations were performed in this study.
Other analyses	17	All additional other analyses performed in the study were outlined in the “Methods” section, page 8 and “Results” section, pages 9 to 12.
Discussion		
Key results	18	Key results with reference to previously outlined study objectives were summarised in the “Discussion” section, pages 13 to 16.
Limitations	19	Limitations of the study, taking into account sources of potential bias and imprecision were outlined in the “Discussion” section, pages 13 to 16.
Interpretation	20	A cautious overall interpretation of the results was given in the “Discussion”, pages 13 to 16 and the “Conclusion” section, page 17.
Generalisability	21	The external validity of the study results was outlined in the “Discussion” section, pages 13 to 16 and table 4, page 15.
Other information		
Funding	22	No financial support for any of the work presented in the present manuscript was obtained, provided on page 19.